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The Special Issue “Experimental and Clinical Treatment of Subarachnoid Hemorrhage after the
Rupture of Saccular Intracranial Aneurysms” provides an excellent insight into the many facets of
aneurysmal subarachnoid hemorrhage. The call for papers on this topic was met with a great response
by researchers and clinicians from all over the world. Among 16 basic science and clinical research
submissions, our editorial team selected nine articles for publication after extensive peer review, which
included three original papers [1–3], three reviews [4–6], two case reports [7,8] and one technical
note [9]. The remaining seven papers were not included, thus yielding a 44% rejection rate.
Two of the three review articles systematically summarize the current literature on preclinical
intracranial and extracranial aneurysm models [4,5]. In a review article on preclinical intracranial
aneurysm models, Strange et al. provides a comprehensive summary of the multitude of available
models to study various aspects of aneurysm formation, growth, and rupture; it serves as an extremely
useful compendium for researchers entering this field of research [5]. The review article on preclinical
extracranial aneurysm models focuses on a small subgroup of models that feature growth and
eventually rupture [4,10]. These models hold special interest for researchers testing novel endovascular
devices as the last step before initiating a first clinical trial.
In an original study using an extracranial aneurysm model in rabbits, researchers confirmed that,
under flow conditions in a bifurcation aneurysm, the organization of an intraluminal thrombus was
strongly dependent on the condition of the aneurysm wall [2]. In another original work featuring
an intracranial aneurysm model on rats, authors investigated how sex hormones influence the
inflammatory reactions in the aneurysm walls and affect the endothelial cells of the vascular walls [3].
The three original papers are basic research; the case studies and technical note are clinical papers [7–9].
This Special Issue represents a compilation of important clinical and preclinical papers by
innovative researchers that enhance our understanding about subarachnoid hemorrhage and
intracranial aneurysms. Their research inspires commitment in our future research for our patients
who face these devastating conditions.
Acknowledgments: We express our gratitude and recognition to all reviewers who participated in the review
process. Their commitment to critically evaluate and comment on the manuscripts substantially improved each
article and enhanced the overall quality of this special issue. We thank Mary Kemper for editing.
Conflicts of Interest: The authors declare that they have no conflict of interest.
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Abstract: Considering the poor outcome of subarachnoid hemorrhage (SAH) due to the rupture
of intracranial aneurysms (IA), mechanisms underlying the pathogenesis of IAs, especially the
rupture of lesions, should be clarified. In the present study, a rat model of IAs in which induced
lesions spontaneously ruptured resulting in SAH was used. In this model, the combination of the
female sex and the bilateral ovariectomy increased the incidence of SAH, similar to epidemiological
evidence in human cases. Importantly, unruptured IA lesions induced in female animals with
bilateral ovariectomy were histopathologically similar to ruptured ones in the presence of vasa
vasorum and the accumulation of abundant inflammatory cells, suggesting the exacerbation of the
disease. The post-stenotic dilatation of the carotid artery was disturbed by the bilateral ovariectomy in
female rats, which was restored by hormone replacement therapy. The in vivo study thus suggested
the protective effect of estrogen from the ovary on endothelial cells loaded by wall shear stress.
β-estradiol or dihydrotestosterone also suppressed the lipopolysaccharide-induced expression of
pro-inflammatory genes in cultured macrophages and neutrophils. The results of the present study
have thus provided new insights about the process regulating the progression of the disease.
Keywords: intracranial aneurysm; subarachnoid hemorrhage; estrogen; female; endothelial
cell; macrophage
1. Introduction
Considering the devastating outcome of subarachnoid hemorrhage (SAH) due to the rupture
of an intracranial aneurysm (IA) [1,2], the development of a novel therapeutic strategy to prevent
the rupture of IAs is mandatory for social health. Mechanisms underlying the rupture of lesions
should, therefore, be clarified. Thus, we attempted to find a cue from well-established epidemiological
evidence. Epidemiological studies have consistently demonstrated a higher incidence of SAH in older
females or postmenopausal females [3–8]. Based on the necessity of clarifying underlying mechanisms
of the rupture of IAs, we examined whether sex difference is indeed present, and if present, why, using
the already-established animal model of IAs [9].
Brain Sci. 2020, 10, 335; doi:10.3390/brainsci10060335 www.mdpi.com/journal/brainsci3
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2. Materials and Methods
2.1. IA Models of Rats and Histological Analysis of Induced IA
All of the following experiments, including animal care and use, complied with the National
Institute of Health’s Guide for the Care and Use of Laboratory Animals and complied with the
National Institute of Health’s Guide for the Care and Use of Laboratory Animals and were approved
by the Institutional Animal Care and Use Committee of the National Cerebral and Cardiovascular
Center (Approved number; #18010 and #19036). The present manuscript also adheres to the ARRIVE
(Animal Research: Reporting of In Vivo Experiments) guidelines for reporting animal experiments.
Ten-week-old male or female Sprague−Dawley (SD) rats were purchased from Japan SLC (Slc:SD,
Shizuoka, Japan) (n = 62 in total). Animals were maintained on a 12-h light/dark cycle, and had free
access to feed and water. To induce IAs, the rats were subjected to ligation of the left carotid artery,
the right external carotid artery and the right pterygopalatine artery, and systemic hypertension by
the combination of a high salt diet and the ligation of the left renal artery under general anesthesia
by the intraperitoneal injection of pentobarbital sodium (50 mg/kg, Somnopentyl, Kyoritsuseiyaku
Corporation, Tokyo, Japan) and the inhalation of Isoflurane (1.5%–2%, #IYESC-0001, Pfizer Inc.,
New York, NY). In some female rats, the bilateral ovariectomy was also applied [9]. Immediately
after the above surgical manipulations, animals were fed chow containing 8% sodium chloride and
0.12% 3-aminopropionitrile (#A0408, Tokyo Chemical Industry, Tokyo, Japan), an irreversible inhibitor
of lysyl oxidase catalyzing the cross-linking of collagen and elastin. Animals that died within one
week after the above surgical manipulations were excluded from the analyses. At 16 weeks after the
surgical manipulations, blood pressure was measured by a tail-cuffmethod without any anesthesia
and was calculated as an average of three measurements. Animals were then deeply anesthetized
by an intraperitoneal injection of pentobarbital sodium (200 mg/kg), and transcardially perfused
with 4% paraformaldehyde solution. The circle of Willis was then stripped from the brain surface
and an IA lesion induced at the anterior communicating artery or the posterior communicating
artery was dissected as a ruptured or unruptured lesion, according to the macroscopic observation
of whether the clot or hemosiderin deposition was present around IA lesions. Here, ruptured
IAs were exclusively induced at these sites examined in the model [9]. All the dead animals after
at least one week of surgical manipulations were autopsied to examine the onset of SAH due to
rupture of induced IAs. Histopathological examination was done after Elastica van Gieson, which
visualizes the internal elastic lamina using 5-um-thick frozen sections. The size of induced lesions was
analyzed using the slices with the maximum area selected from serial sections using ImageJ software
(https://imagej.nih.gov/ij/index.html).
2.2. Immunohistochemistry
At the indicated period after the aneurysm induction, 5-μm-thick frozen sections were prepared.
After blocking with 3% donkey serum (#AB_2337258, Jackson ImmunoResearch, Baltimore, MD, USA),
slices were incubated with primary antibodies, followed by incubation with secondary antibodies
conjugated with a fluorescence dye (Jackson ImmunoResearch). Finally, fluorescent images were
acquired using a confocal fluorescence microscope system (FV1000 or FV3000, Olympus, Tokyo, Japan).
The following primary antibodies were used: mouse monoclonal anti-CD68 antibody (#ab31630,
Abcam, Cambridge, UK), rabbit polyclonal anti-myeloperoxidase (MPO) antibody (#ab9535, Abcam),
rabbit polyclonal anti-tumor necrosis factor (TNF)-alpha antibody (#ab6671, Abcam), mouse monoclonal
anti-smooth muscle α-actin (SMA) antibody (#M0851, Dako, Agilent, Santa Clara, CA, USA).
The following secondary antibodies were used; Alexa Fluor 488-conjugated donkey anti-mouse
IgG H&L antibody (#A21202, Thermo Fisher Scientific, Waltham, MA, USA), Alexa Fluor 488-conjugated
donkey anti-rabbit IgG H&L antibody (#A21206, Thermo Fisher Scientific), Alexa Fluor 594-conjugated
donkey anti-mouse IgG H&L antibody (#A21203, Thermo Fisher Scientific).
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2.3. Stenosis Model of the Carotid Artery of a Rat
Female rats underwent a bilateral ovariectomy and sham operation, and were then maintained for
7 days before subjecting to the model. The left common carotid artery of rats was then ligated using a
10-0 nylon thread with 25 gauge needle put on the side of the artery and stenosis was established by
removing only the needle [10,11]. The post-stenotic dilatation of the carotid artery was observed for
30 min after ligation.
2.4. Hormone Replacement Therapy
Estradiol valerate (1 mg/kg, #224136400 Pelanin Depot, Mochida Pharmaceutical Co., Ltd.,
Tokyo, Japan) was intramuscularly injected every 7 days in a female rat that underwent the
bilateral ovariectomy.
2.5. Cell Line and Culture
RAW264.7 cell line (#TIB-71), used as a macrophage, and HL-60 cell line (#CCL-240), used as a
neutrophil, were purchased from ATCC (Manassas, VA, USA) and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) (#044-32955, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan)
supplemented with 10% or 20% fetal bovine serum (#FB-1365/500, Biosera, Nuaille, France), respectively.
2.6. Quantitative Real Time (RT)-PCR Analysis in Cultured Cells
RAW264.7 cells or HL-60 cells were pre-treated with β-estradiol (E2, 50 μg/mL, #E0025, Tokyo
Chemical Industry) or 5α-Dihydrotestosterone (DHT, 50 μg/mL, #A0462, Tokyo Chemical Industry)
for 24 h or 3 h, respectively. Cells were then stimulated with vehicle (Veh), LPS (1 μg/mL, #L2654,
Sigma Aldrich, St. Louis, MO, USA) or TNF-α (100 ng/mL, R&D SYSTEMS, Minneapolis, MN, USA)
for additional 60 min.
Total RNA was purified from stimulated cells and reverse-transcribed using a RNeasy Mini Kit
(#74106, QIAGEN, Hilden, Germany) and a High-capacity cDNA Reverse Transcription Kit (#4368813,
Life Technologies Corporation, Carlsbad, CA, USA), according to the manufacturers’ instructions. For
quantification of gene expression, quantitative RT-PCR was performed on a LightCycler 480 (Roche,
Indianapolis, IN, USA) with a TB Green Premix Ex Taq II (#RR820, TAKARA BIO INC., Shiga, Japan).
Expression of Actb (a gene coding β-actin) in experiments using the RAW264.7 cell line, or ACTB in
experiments using the HL-60 cell line, were used as internal controls. For quantitation, the second
derivative maximum method was used for determining the crossing point.
Primer sets used are listed as follows: forward 5′-CACCTCAGGGAAGAATCTGG-3′ and reverse
5′-CATTCCTGAGTTCTGCAAAGG-3′ for Tnf ; forward 5′-AAAGGGAGCTCCTTAACATGC-3′
and reverse 5′-CTTCCTGGGAAACAACAGTGG-3′ for Il1b; forward
5′-AATGATGTGTACGGCTTCAGG-3′ and reverse 5′-CTGTACAAGCAGTGGCAAAGG-3′ for Ptgs2
(a gene encoding cyclooxygenase-2 (COX-2)); forward 5′-GCACAGACCTCTCTCTTGAGC-3′
and reverse 5′-ACCTGCTGCTGCTACTCATTCACC-3′ for Ccl2 (a gene encoding
monocyte chemoattractant protein-1 (MCP-1)); 5′-ACGACCAGAGGCATACAGGGA-3′ and
5′-CCCTAAGGCCAACCGTGAAA-3′ for Actb; forward 5′-TCAGCAATGAGTGACAGTTGG-3′ and
reverse 5′-ATAGGCTGTTCCCATGTAGCC-3′ for TNF; forward 5′-CAAGCTGGAATTTGAGTCTGC-3′
and reverse 5′-ATTCAGCACAGGACTCTCTGG-3′ for IL1B; forward
5′-ACACCCTCTATCACTGGCATCC-3′ and reverse 5′-AACATTCCTACCACCAGCAACC-3′ for
PTGS2; forward 5′-AGCTTCTTTGGGACACTTGC-3′ and reverse 5′-ATAGCAGCCACCTTCATTCC-3′
for CCL2 and forward 5′-CATACTCCTGCTTGCTGATCC-3′ and reverse
5′-GATGCAGAAGGAGATCACTGC-3′ for ACTB.
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2.7. Statistical Analysis
Data are shown as the mean ± SEM. Statistical comparisons between two or more groups
were conducted using a Welch’s t-test or the Tukey-Kramer method, respectively, with JMP Pro 14
(SAS Institute Inc., Cary, NC, USA). A p value less than 0.05 was defined as statistically significant.
3. Results
3.1. Highest Incidence of SAH in Female Rats with the Bilateral Ovariectomy
In reference to established epidemiological evidence, the risk of SAH is higher in postmenopausal
or older females than in males and in females before menopause [3–8], we first examined whether the
sex difference in the incidence of SAH could be reproduced or not in a rat model of IAs [9] as in human
cases, to escape many uncontrollable confounding factors. Rats were subjected to an IA model and the
incidence of IA lesions at the anterior or the posterior communicating artery complex and the onset of
SAH due to rupture of IA lesions at each site were examined.
In male rats, 15 among 18 animals (83.3%) developed IAs at the anterior or the posterior
communicating artery and 3 of these animals had multiple lesions at both artery complex. SAH
occurred in 5 among 18 rats or IA lesions (27.8%) during the observation period of 16 weeks after the
induction (Figure 1a–c). In female rats without the bilateral ovariectomy, 9 among 17 animals (52.9%)
developed IAs at the anterior or the posterior communicating artery and one of these animals had
multiple lesions. SAH occurred in 1 among 17 rats (5.9%) or 10 lesions (10.0%) in total in this group
(Figure 1a–c). In female rats with bilateral ovariectomy, 9 among 14 animals (64.3%) developed IAs at
the anterior or the posterior communicating artery and 1 of these animals had multiple lesions. SAH
occurred in 8 among 14 rats (57.1%) or 10 lesions (80.0%) in total in this group (Figure 1a–c). Although
the difference in sex or the implementation of ovariectomy did not influence the development of
IAs, the combination of these two factors significantly facilitated the rupture of induced IAs in a rat
model. The incidence of SAH per induced IA lesions was thus the highest in female rats with bilateral
ovariectomy in spite of the significantly lower systolic blood pressure in female rats than in male rats
(Figure 1).
3.2. Exacerbation of the IA Pathology in Female Rats with the Bilateral Ovariectomy
To explore mechanisms underlying the effect of sex difference or the implementation of ovariectomy
in female animals on the onset of SAH, the histopathological examinations of induced IA lesions
were done. The size of induced IAs was significantly larger in female rats with bilateral ovariectomy
than that in other groups (Figure 2a,b). Most IA lesions induced in female animals with bilateral
ovariectomy ruptured, resulting in SAH (Figure 1). Intriguingly, the remaining unruptured lesions
induced were apparently bigger than the ones induced in female animals without the ovariectomy or in
male animals (Figure 2a). Immunohistochemical analyses revealed the accumulation of MPO-positive
neutrophils and CD68-positive macrophages in arterial walls of the lesions, even in unruptured
IA lesions specifically from female animals with bilateral ovariectomy, similarly to ruptured ones
(Figure 2c). Such an accumulation of inflammatory cells was only limited in unruptured IA lesions
from male animals or female animals without ovariectomy (Figure 2c). Consistently, expression
of pro-inflammatory factor TNF-α, which is related with the pathogenesis [12–14], was higher in
unruptured lesions from female animals with bilateral ovariectomy than that in male animals or female
animals without ovariectomy (Figure 2d). In addition, expression of TNF-α in unruptured lesions
from female animals with bilateral ovariectomy was similar to that in ruptured lesions (Figure 2d).
In addition, the presence of vasa vasorum with SMA-positive media, which we identified as a
histopathological characteristic of ruptured IA lesions [9], could be detected even in unruptured
lesions only from female animals with the bilateral ovariectomy, and not in female animals without
ovariectomy or male animals (Figure 2e). The unruptured IA lesion induced in female animals with
6
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the bilateral ovariectomy thus resembles ruptured lesions. In other words, the bilateral ovariectomy in
female animals promotes events underlying rupture of the lesions.
 
Figure 1. The incidence of intracranial aneurysms, the cumulative incidence of subarachnoid
hemorrhage and the rate of rupture of induced lesions. To induce intracranial aneurysms, 10-week-old
male (n = 18) or female Sprague−Dawley rats (n = 31) were subjected to the ligation of the left carotid
artery, the right external carotid artery and the right pterygopalatine artery, and systemic hypertension
by the combination of a high salt diet and the ligation of the left renal artery. In some female rats
(n = 14), the bilateral ovariectomy was also applied. Animals were maintained for 120 days after
surgical manipulations. The incidence of intracranial aneurysms (a), the cumulative incidence of
subarachnoid hemorrhage (SAH) (b), the rate of rupture of induced lesions (c) or systolic blood pressure
(sBP) (d) in each group; male rats, female rats without ovariectomy (female) or female rats with the
bilateral ovariectomy (ovariectomized), are shown. Bars in (d) indicate the mean ± SEM. Statistical
analysis was done by the Tukey-Kramer method in (c,d). * p < 0.05, ** p < 0.01, *** p < 0.001.
3.3. Disturbance in Endothelial Function by the Bilateral Ovariectomy in Female Rats
A series of studies about IAs has clarified the involvement of macrophage-mediated chronic
inflammatory responses in the pathogenesis of the disease and also the potential contribution of
wall shear stress to this process [15–20]. To explore mechanisms regulating ovariectomy-mediated
facilitation of rupture of lesions, we examined the effect of the bilateral ovariectomy on endothelial
cell function by using the stenosis model of the carotid artery in which the post-stenotic dilatation
occurs in response to increased wall shear stress-loading [10,11]. In female rats without ovariectomy,
the post-stenotic dilatation of the carotid artery could be observed at 30 min after the partial ligation,
as expected (Figure 3a). However, in female animals with the bilateral ovariectomy, the post-stenotic
dilatation was partially but significantly restricted (Figure 3a). Importantly, hormone replacement
therapy by Estradiol valerate restored ovariectomy-induced restriction of post-stenotic dilatation
(Figure 3b). The bilateral ovariectomy thus disturbed endothelial cell function.
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Figure 2. The exacerbation of the pathology of intracranial aneurysm in female rats with the bilateral
ovariectomy. Ten-week-old female Sprague−Dawley rats were subjected to the aneurysm model. At
120 days after the surgical manipulations, specimens of induced lesions were harvested. (a,b) The
macroscopic image of induced lesions (a) and their size (b) in each group; male rats (n = 18), female rats
without ovariectomy (female, n = 10) or female rats with the bilateral ovariectomy (ovariectomized,
n = 10). Bar, 1.0 mm (a). The white arrows and the black ones in (a) indicate the unruptured and
the ruptured lesions, respectively. Bars in (b) indicate the mean ± SEM. Statistical analysis was done
by the Tukey–Kramer method. ***; p < 0.001. (c,d) show similarity of unruptured lesions induced
in female animals with the bilateral ovariectomy with ruptured ones. The representative images
of immunostaining for a marker for neutrophil, myeloperoxidase (MPO, green in (c)), a marker for
macrophage, CD68 (red in (c)), TNF-α (green in (d)), a marker for smooth muscle cell, smooth muscle
alpha-actin (SMA, red in (e)), nuclear staining by DAPI (blue) or merged images are shown. The
immunostaining without a 1st antibody served as a negative control and the representative images of
this staining are shown in the lowest panels. Ruptured lesions were from female rats with the bilateral
ovariectomy. The arrow in (e) indicates vasa vasorum with SMA-positive media. The magnified images,
corresponding to a square in the upper panels, are shown in the lower panels. Bar, 20 μm.
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Figure 3. The disturbance of post-stenotic dilatation by the bilateral ovariectomy in female
rats. 10-week-old female Sprague−Dawley rats were subjected to the bilateral ovariectomy or a
sham-operation. On the 7th day, animals underwent the carotid ligation and the post-stenotic dilatation
was observed for following 30 min (a). In some animals, hormone replacement therapy (HRT) was
applied after the bilateral ovariectomy (b). Representative macroscopic images of the carotid artery
before (pre) and 30 min after the ligation (30 min) are shown. The diameter of the carotid artery was
calculated before (pre), just after (0 min) and 30 min after the ligation (30 min). Bars indicate the mean
± SEM (n = 4). Statistical analysis was done by a Welch’s t test. ***; p < 0.001.
3.4. Suppressive Effect of Sex Hormone on Inflammatory Responses in Macrophages and Neutrophils
Further, we examined the effect of the sex hormone, E2 (the hormone from the ovary) or DHT
(the hormone from the testis), on inflammatory responses by cultured macrophages (RAW264.7
cell line) or neutrophils (HL-60 cell line). In RAW264.7 cells, although LPS-induced expressions of
pro-inflammatory genes are related with pathogenesis, Tnf (TNF-α) [12–14], Il1b (IL-1β) [21], Ptgs2
(COX-2) [22] or Ccl2 (MCP-1) [20,23]—even with the pre-treatment by E2, the addition of E2 could
significantly suppress expressions of all of these genes compared with those in the vehicle-treated
cells (Figure 4a). The pre-treatment with DHT significantly suppressed expression of Ccl2 among four
genes examined (Figure 4a). In HL-60 cells, the pre-treatment of E2 or DHT suppressed LPS-induced
expression of pro-inflammatory genes (Figure 4b) in RAW264.7 cells. The suppressive effect of E2 was
stronger than that of DHT as well (Figure 4b). Consistently, expression of TNF-α was higher in lesions
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from female animals with bilateral ovariectomy than that in male animals or female animals without
ovariectomy (Figure 2d). The results of the in vitro study suggest the suppressive effect of the sex
hormone on the inflammatory responses in lesions promotes the pathology.
Figure 4. Suppressive effect of the sex hormone on expressions of pro-inflammatory genes in cultured
macrophages or neutrophils. RAW264.7 cells (a) or HL-60 cells (b) were pre-treated with β-estradiol
(E2, 50 μg/mL) or 5α-dihydrotestosterone (DHT, 50 μg/mL) for 24 h or 3 h, respectively. Cells were then
stimulated with vehicle (Veh), LPS (dose) or TNF-α (dose) for an additional 60 min. Expressions of
pro-inflammatory genes were examined by quantitative RT-PCR analyses. Bars indicate the mean ±
SEM (n = 4). Statistical analysis was done by a Tukey-Kramer method. *; p < 0.05, **; p < 0.01, ***; p <
0.001. n.s.; statistically not significant.
4. Discussion
The epidemiological findings that post-menopausal females have a higher incidence of IAs than
do males or females with menopause [3–8] was reproduced in the rat model in the present study, in
which the bilateral ovariectomy in female animals significantly increased rupture of IAs. In another
animal model, in which SAH was induced by the combination of the bilateral ovariectomy in female
animals with the intrathecal injection of elastase, hormone replacement therapy by estrogen was shown
to ameliorate the incidence of rupture [24]. The different animal models of SAH have thus consistently
demonstrated the promoting effect of the bilateral ovariectomy on the rupture of IAs, confirming the
crucial contribution of estrogen to the rupture of IAs. The previous experimental studies using an
animal model of IAs have also demonstrated the facilitation of the formation and the progression of IAs
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by bilateral ovariectomy, which could be ameliorated by hormone replacement therapy [25,26]. In this
report, similar to the present study, the protective role of estrogen in endothelial cell function has been
indicated [26]. Furthermore, in human cases, the protective effect of hormone replacement therapy to
compensate for the defect in functions of the ovary on the onset of SAH was reported [4,27], suggesting
the clinical relevance of the present study. Hormone replacement therapy has adverse effects, such
as the increased risk of breast cancer, ischemic stroke and ischemic heart disease, which makes the
application of this therapy for the treatment of IAs in post-menopausal women controversial. However,
the present study has provided experimental evidence for the potential of hormone replacement
therapy as an option of treatment to prevent the onset of SAH in post-menopausal women.
Recent experimental studies mainly using an animal model of IAs [28,29] have clarified the
involvement of chronic inflammatory responses in the process regulating the initiation, progression
or rupture of IAs [15,16,18,30,31]. Additionally, hemodynamic force, especially wall shear stress,
is considered a mediator of IA formation and progression, mainly through a series of studies by
computational fluid dynamics analyses [17,32]. In the present study, we clarified the suppressive effect
of E2 or DHT on expressions of pro-inflammatory factors in cultured macrophages and neutrophils
(Figure 4). Additionally, the combination of female sex with bilateral ovariectomy exacerbated
inflammatory cells like macrophages or neutrophils in lesions (Figure 2). Here, the in vitro finding
that the suppressive effect of E2 was stronger than that of DHT may be responsible for the highest
incidence of rupture in female animals with bilateral ovariectomy. Furthermore, in the stenosis model,
the bilateral ovariectomy in female animals disturbed the high wall shear stress-induced post-stenotic
dilatation of the carotid artery (Figure 3), suggesting the malfunction of endothelial cells. Intriguingly,
the results of the present study have implied the role of the maladaptation of endothelial cells to shear
stress-loading at the bifurcation sites as a trigger of molecular events, leading to the progression and
rupture of the lesions. The ovariectomy in female animals, therefore, facilitates the pathogenesis of IAs
in multiple steps by influencing the functions of endothelial cells and inflammatory cells.
5. Conclusions
To explore mechanisms regulating rupture of IAs, we have used a rat model and revealed the
facilitation of the progression or rupture of the lesions by the combination of the female sex and the
bilateral ovariectomy. Furthermore, we have clarified the point of actions of sex hormone as endothelial
cells and inflammatory cells to inhibit the progression of the pathogenesis. The results of the present
study have thus provided new insights about mechanisms regulating the progression of the disease.
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Abstract: Based on the relationship between the posterior clinoid process and the basilar artery (BA)
apex it may be difficult to obtain proximal control of the BA using temporary clips. Endovascular BA
temporary balloon occlusion (TBO) can reduce aneurysm sac pressure, facilitate dissection/clipping,
and finally lower the risk of intraoperative rupture. We present our experience with TBO during
aneurysm clipping of posterior circulation aneurysms within the setting of a hybrid operating room
(hOR). We report one case each of a basilar tip, posterior cerebral artery, and superior cerebellar
artery aneurysm that underwent surgical occlusion under TBO within an hOR. Surgical exposure of
the BA was achieved with a pterional approach and selective anterior and posterior clinoidectomy.
Intraoperative digital subtraction angiography (iDSA) was performed prior, during, and after
aneurysm occlusion. Two patients presented with subarachnoid hemorrhage and one patient
presented with an unruptured aneurysm. The intraluminal balloon was inserted through the femoral
artery and inflated in the BA after craniotomy to allow further dissection of the parent vessel and
branches needed for the preparation of the aneurysm neck. No complications during balloon inflation
and aneurysm dissection occurred. Intraoperative aneurysm rupture prior to clipping did not occur.
The duration of TBO varied between 9 and 11 min. Small neck aneurysm remnants were present in
two cases (BA and PCA). Two patients recovered well with a GOS 5 after surgery and one patient died
due to complications unrelated to surgery. Intraoperative TBO within the hOR is a feasible and safe
procedure with no additional morbidity when using a standardized protocol and setting. No relevant
side effects or intraoperative complications were present in this series. In addition, iDSA in an hOR
facilitates the evaluation of the surgical result and 3D reconstructions provide documentation of
potential aneurysm remnants for future follow-up.
Keywords: aneurysm clipping; posterior circulation aneurysm; temporary balloon occlusion;
intraoperative digital subtraction angiography; hybrid operating room
1. Introduction
Aneurysms of the posterior circulation, such as the basilar artery (BA), present a particular surgical
challenge [1,2]. They represent 5–8% of all intracranial aneurysms and more than 50% of those in the
posterior circulation [3,4]. Posterior circulation aneurysms are known to have a higher risk of rupture [5].
According to recently published scores such as PHASES [6] or UIATS [7], preventive endovascular
or surgical methods can be performed in patients at risk, to minimize the chance of aneurysm
rupture. The difficulties of microsurgical clipping are mainly caused by anatomical conditions and a
demanding approach [8]. Surgical complexity varies according to size, shape, and localization of the
Brain Sci. 2020, 10, 334; doi:10.3390/brainsci10060334 www.mdpi.com/journal/brainsci15
Brain Sci. 2020, 10, 334
aneurysm, degree of intraoperative brain swelling, and the microsurgical experience of the surgeon [9].
Moreover, standard clipping could fail due to insufficient proximal control and lead to incomplete
occlusion or intraoperative aneurysm rupture [10]. Nevertheless, microsurgical clipping is still more
accessible worldwide, especially in developing countries [11].
The ISAT (International Subarachnoid Aneurysm Trial) reported a higher rupture rate for basilar
apex aneurysm in correlation with aneurysm size [12]. Increased morbidity and mortality, and worse
clinical outcome was also reported after surgical clipping compared to endovascular coiling of a posterior
circulation aneurysm [12]. These findings initiated the use of endovascular treatment for a basilar
apex region aneurysm [13]. The fact that fewer neurosurgeons are performing microsurgical clipping
of basilar apex aneurysm supports the trend for treating basilar artery aneurysms endovascularly
rather than surgically [14]. The safety of endovascular occlusion of BA aneurysms has been proven,
although long-term sustainability and efficacy remain unclear [13–17].
Up to 50% recanalization and regrowth of a coiled aneurysm has been reported [17–20].
The annual risk of bleeding in a partially coiled or recanalized aneurysm is reported to range from
2.1–15% [17,18,21–23]. This is relatively high and similar to rates for an unruptured aneurysm [5,24–29].
The exact location of the aneurysm is the key factor when deciding which surgical approach
to take. The prevention of any injury to the brainstem and its perforators is crucial [30].
Different approaches to BA aneurysms have been described including the pterional approach
introduced by G. Yasargil [31], the subtemporal approach pioneered by C. Drake [32], as well
as lateral supraorbital [33], orbitozygomatic [34,35], modified presigmoid [36], transpetrosal [37] or
transzygomatic transcavernous approaches, [13] and many others [38,39].
Various methods of temporary vessel occlusion or local blood flow interruption have been
applied to facilitate a microsurgical approach to a large aneurysm in a narrow and deep location.
Also, adenosine-induced cardiac arrest [40], hypothermic circulatory arrest [41], temporary clip
placement [42], and temporary balloon occlusion [43] have been described. The relationship between the
posterior clinoid process and the BA apex may limit the access for temporary clips [39]. An endovascular
technique using balloon inflation in the parent vessel of the aneurysm can achieve proximal and distal
control during surgery and, therefore, eliminate the need for temporary clipping [43]. Intraoperative
temporary balloon occlusion (TBO) of the parent vessel might lower the risk of intraoperative rupture,
reduce pressure in the aneurysm sac, and facilitate dissection and microsurgical clipping. The aim
of this study is to describe the technical issues, setup, and experience of intraoperative TBO during
surgical occlusion of complex posterior circulation aneurysms within the hybrid operating room (hOR).
2. Materials and Methods
We report three cases of intracranial aneurysms of the posterior circulation that underwent
clipping with the concurrent use of TBO in our department between 2013 and 2016. The first patient
suffered subarachnoid hemorrhage (SAH) after the rupture of a basilar tip aneurysm (16 × 16 × 15 mm).
Endovascular occlusion was not indicated due to the risk of occlusion of the posterior cerebral
artery (PCA) and the superior cerebellar artery (SCA). The second case presented with a ruptured,
partially thrombosed BA aneurysm (11 × 8 × 8 mm) with secondary wall hematoma and no SAH. As in
the previous case, endovascular occlusion was considered not possible due to the risk of SCA occlusion
caused by duplicate origin from the aneurysm fundus. The third patient had an incidental right
proximal PCA (P1) aneurysm (4 × 5 × 5 mm). Endovascular treatment was scheduled, but 3D digital
cerebral angiography (DSA) showed the SCA originating from the aneurysm sac and the treatment
strategy was changed to surgery occlusion. Complex anatomical vascular findings were considered
for the decision to choose a combined endovascular and microsurgical procedure within the (hOR) in
these three cases (Table 1).
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The technical aspects of performed combined approaches in the hOR have been described by our
group in an earlier publication [44]. The main unit consists of a 360◦ radiolucent carbon fiber table
(Alphamaquet 1150, Maquet AG, Switzerland) that is coupled with the C-arm angiography system
(Allura Xper FD20, Philips, Netherlands). A radiolucent head holder and pins are required for optimal
acquisition of angiograms and intraoperative CT scans (Mayfield, Integra GmbH, Ratingen, Germany).
A 7-Fr sheath is placed in the right or left femoral artery in preparation for intraoperative endovascular
balloon occlusion and control DSA. All cases underwent an intraoperative DSA (iDSA) and CT (iCT)
scan before they were transferred to the intensive care unit.
2.1. Illustrative Cases
The surgical approach and endovascular techniques were similar in all three cases.
2.1.1. Surgical Procedure
After the positioning of the patient′s head in a carbon clamp in the hOR, a right fronto-temporal
craniotomy and selective extradural anterior clinoidectomy were performed. The proximal Sylvian
fissure was opened, and the chiasmatic cistern incised, followed by dissection of the optic and
oculomotor nerve, and carotid artery. Once the posterior clinoid process was exposed, a posterior
clinoidectomy was completed with a 2 mm drill. The afterward visible BA, PCA′s, SCA′s, and aneurysm
were inspected. After craniotomy, the first iDSA was performed by cannulation of the right femoral
artery with a 7-Fr sheath and inserting a 5F diagnostic catheter in one of the vertebral arteries. The first
iDSA showed the previously identified aneurysm and in Case 1 a progression of the dissecting basilar
tip aneurysm with a new bleb. The diagnostic catheter was exchanged for a soft guiding catheter
(Neuron 6F 058, Penumbra, Alameda CA, USA). An ASCENT® 4 × 7 balloon (DePuy Synthes) and was
then placed in the middle or distal segment of the BA and inflated under fluoroscopy to interrupt blood
flow. The dual lumen design of the ASCENT balloon allows the distal flushing of the occluded vessel
by saline. In the meantime, the BA or PCA aneurysm neck, which was significantly softened, as well
as PCA and SCA branches were further dissected. The aneurysms were occluded in a microtechnical
fashion with straight standard titanium 790-Yasargil-Clips (Aesculap, Tübingen, Germany) under
visualization of both SCA branches. The balloon was deflated after 9, 10, and 11 min of TBO. An iDSA
and intraoperative 3D-angiography in Case 1 showed complete occlusion of the BA aneurysm with
patent PCA and SCA branches (Figure 1). The iDSA in Cases 2 and 3, revealed a small remnant at the
aneurysm neck to preserve the SCA exit, no sign of aneurysm perfusion, and patent PCA and SCA
branches (Figures 2 and 3). The dura was sutured, the bone flap fixed, and the wound sutured using a
standard multilayered technique. The iCT scan documented no hemorrhage or midline shift.
Case 1
History
This 53-year-old patient presented with a SAH after a sudden loss of consciousness at home.
The patient was intubated upon admission with a Glasgow Coma Scale (GCS) score of 3. The CT scan
showed a SAH caused by a ruptured basilar tip aneurysm (Fisher grade IV). A DSA was performed
after the patient improved to a GCS of 10 following two days of conservative treatment and CSF
drainage after ventriculostomy. A basilar tip aneurysm (16 × 16 × 15 mm) with the PCA and SCA
bilaterally arising from the aneurysm base was identified. Indication for surgical occlusion was decided
after interdisciplinary case discussion. The surgical procedure in the hOR had to be postponed for six
days due to severe vasospasms in the posterior circulation.
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Figure 1. Case 1. Preoperative ap and lateral DSA of the basilar tip aneurysm (A,B). Preoperative 3D
angiography of the basilar aneurysm presenting the bilateral origin of the PCA and SCA from the
aneurysm base (C,D). Intraoperative angiography showing the endovascular placement of the balloon
and occlusion of the basilar artery (E,F). Intraoperative DSA after clipping and closure of the balloon
showing complete occlusion of the aneurysm in ap and lateral view with all branches open (G–I).
Intraoperative picture of the opened skull, placed fish hooks, spatula and clip (J).
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Figure 3. Case 3. Preoperative DSA ap and lateral projections of the proximal right side PCA aneurysm
(P1 branch) (A,B). Preoperative 3D-DSA of the PCA aneurysm, showing the right SCA leaving the
P1 segment from the aneurysm sidewall (C,D). Intraoperative DSA presenting the placement of the
balloon and occlusion of the BA after balloon inflation (E,F). Intraoperative angiography after clipping
and balloon removal demonstrating occlusion of the aneurysm and patency of the BA and PCA (G–I).
Intraoperative 3D-DSA showing a small remnant at the aneurysm neck to preserve the patency of the
SCA (J,K). Abbreviations: DSA = digital subtraction angiography, PCA = posterior cerebral artery,
SCA = superior cerebellar artery.
Postoperative Course
Further course on the ICU was unsuccessful. Consciousness persisted at a low level of GCS
5 due to severe vasospasm and the deterioration of cerebral perfusion on CT was observed within
48 h after surgery. Despite of endovascular spasmolysis with Nimodipine was performed no clinical
improvement could be observed. During the next days, the general condition of the patient deteriorated
due to pneumonia and respiratory failure leading to death eight days after surgery.
Case 2
History
A 44-year-old patient was admitted to the emergency room with a thunderclap headache,
neck pain, vomiting, and paresthesia in the right arm. The patient had a GCS score of 15 without
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meningism or any neurological deficits. Further investigations (CT, CTA, and DSA) excluded an
SAH but showed a dissecting, partially thrombosed BA aneurysm (11 × 8 × 8 mm) with a secondary
wall hematoma. Cerebral angiography revealed a duplicate origin of the SCA out of the aneurysm
fundus. Treatment options were discussed in the interdisciplinary neurovascular board. In principal,
endovascular occlusion by coiling or stent-assisted coiling was considered—with a high risk of SCA
occlusion and secondary cerebellar ischemia. Therefore, the group decided to recommend microsurgical
aneurysm clipping under endovascular TBO in the hOR.
Postoperative Course
The patient was hospitalized for one more week. During this time, the patient suffered an epileptic




After the occurrence of vertigo, this 48-year-old patient underwent an MRI scan which revealed
an incidental right PCA aneurysm. The patient was referred to our Institution, and the history and
clinical examination excluded any episodes of headache, epileptic seizure, or neurological deficits.
Further aneurysm imaging with DSA showed a saccular right BA aneurysm at the origin of the P1
segment of the PCA (4 × 5 × 5 mm). The pre-interventional 3D-DSA depicted the origin of the SCA
directly arising from the aneurysm fundus, as well as a hypoplastic bilateral posterior communicating
artery. After the case discussion with the neurovascular board, surgical occlusion with TBO in the hOR
was recommended.
Postoperative Course
Postoperatively, the patient presented with a GCS score of 15, discrete ptosis, anisocoria, and double
vision. A further CT scan confirmed otherwise regular findings (the ophthalmological symptoms were
mainly caused by an impairment of oculomotor nerve function). The oculomotor nerve dysfunction
had resolved by itself by the three-month follow up.
3. Results
All cases underwent combined surgical and endovascular procedures in our hOR. After craniotomy
and dissection of the parent vessel and aneurysm the intraluminal balloon was inserted through the
femoral artery and inflated in the BA. In all three cases, intraoperative TBO was successfully performed
without complications. No aneurysm rupture prior to clipping, or any other intra- or postoperative
problems (necessary clip repositioning, parent vessel or branch occlusion, thromboembolic event,
or re-bleeding) occurred. The mean duration of TBO was 10 min (Table 2). Upon inflation of the
balloon, the intraluminal pressure releases and the aneurysm softens rapidly, which gives the surgeon
more space and flexibility to explore the aneurysm and vessels branching out of the aneurysm base.
Intraoperative DSA following clipping confirmed complete aneurysm occlusion with patent parent and
branch vessels. In two cases, a small remnant at the aneurysm neck was visible in the intraoperative
3D angiography, which was necessary to preserve the branch origin. Two patients showed good
postoperative recovery with GOS 5 and one patient died due to severe vasospasm and pneumonia.
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Complete occlusion of the
aneurysm
All branches open





Small remnant at the neck to
preserve the SCA exit
No aneurysm perfusion
All branches open





Small remnant at the neck to
preserve the SCA exit
No aneurysm perfusion
All branches open




iDSA = intraoperative digital subtraction angiography, TBO = temporary balloon occlusion, SCA = superior
cerebellar artery.
4. Discussion
The findings of this technical note support the fact that TBO is a feasible, safe, and reliable method
for the clipping of posterior aneurysms that are technically demanding and complex due to size or
anatomy. In our institution, TBO with a combined endovascular and surgical approach is also used
for giant and complex recurrent middle cerebral artery (MCA) or anterior communicating artery
aneurysms. In cases with a ruptured MCA aneurysm and surrounding hematoma, endovascular TBO
facilitated clipping following hematoma evacuation and prevented an intraoperative rupture of fragile
high-risk aneurysms.
In the case of intraoperative rupture, TBO could effectively control acute bleeding and increase
the safety and accuracy of clip placement. In one case report with the intraoperative rupture of a
paraclinoid aneurysm, TBO provided a salvage procedure for adequate hemostasis with additional
intraluminal support to preserve the parent artery during clip placement [43].
In our opinion, microsurgery should still be viewed as a valuable option in the management
of posterior circulation aneurysms. Various authors have reported good radiological and clinical
outcomes for BA clipping with or without additional bypass [33,45–51]. Overall, the most common
complications in this location are perforator and branch ischemia-related events and cranial nerve
deficits, often involving oculomotor nerve palsies [47,52–54]. One case of transient oculomotor nerve
palsy occurred in our series.
The angiographic obliteration rate of posterior circulation aneurysm has been reported with
a range from 91.9–98.1% [8,29,45,55]. However, other reports also cited 11.5% transient and 7.8%
permanent neurological deteriorations [45].
Circumferential exposure of the aneurysm, including branches and perforators, is necessary prior
to a safe and efficacious clip application. Dissection and visualization of where they exit the aneurysm
can be very demanding. Various methods have been described to support the surgeon during the
clip application. Additional endovascular assistance can help prospective vascular neurosurgeons to
become more confident and proficient in these cases. Temporary parent vessel occlusion seems to be a
safe procedure. Interestingly, a study with a mean follow-up of 53 months showed that a temporary
artery occlusion time (mean 16.1 min) had no effect on overall long-term clinical outcomes [56].
The “gold standard” for proximal vessel control is a temporary clip application, which is not
always feasible, especially in areas with limited access [57]. Proximal parent vessel ligation [58] can be
considered for treating giant aneurysms. Transient asystole with adenosine [40,59,60], deep hypothermic
circulatory arrest [61], or rapid ventricular pacing [62] are other techniques also described in the literature
but have higher risk profiles for side effects such as atrial or ventricular fibrillation, arrhythmias,
and prolonged hypotension [62]. In addition, the risk of stroke can increase after a circulatory arrest,
and the resulting need for a multidisciplinary team of surgeons and technologists is logistically
23
Brain Sci. 2020, 10, 334
challenging and expensive [63]. Perioperative morbidity and mortality for circulatory arrest has been
described as ranging from 8.3–17% [41,61]. The risk of side effects of these different techniques has to
be weighed against the significant chance of intraoperative aneurysm rupture, incomplete clipping, or
unintended branch occlusion due to poor visualization.
In comparison, TBO presents a simple, fast, and inexpensive technique with no need for special
anesthesiological monitoring or training and can be performed at any time in every center with
endovascular expertise. Although temporary clipping will remain the routinely used technique,
TBO may be more accurate for complex and large aneurysms, especially in the posterior circulation
and to prevent premature rupture. In posterior circulation aneurysm clipping, proximal control with
temporary clipping is often not possible due to the complex anatomy, skull base proximity, and location
near the brain stem and cranial nerves [64]. The temporary clip itself may hinder the placement of the
permanent one due to the limited surgical corridor [65]. In these cases, TBO can provide a reliable
alternative. Proximal control with TBO can be achieved before craniotomy with minimal obstruction
of the surgical field and less brain retraction.
Possible side effects of TBO and temporary clipping include wall injury of the parent vessel
or thromboembolic events causing postoperative ischemic deficits. MacDonald et al. compared
the degree of acute endothelial injury after temporary vessel occlusion with external clipping and
endovascular balloon occlusion in a pig model [66]. The results revealed that vessel injury worsened
with time and was more prevalent adjacent to the clip; as compared to the widespread pattern with
TBO [66]. There is the concern of a higher risk of ischemic complications with balloon occlusion in
perforator-rich vessels like MCA and BA, but neither MCA nor BA TBO interventions at our institution
led to perforator infarctions.
The TBO technique was first described in 1986 by Kinjo et al. [67], by Shucart et al. in 1990 [68],
and in many other case series since then. More recently, another group has reported on the use of TBO
in the hybrid OR [69]. Table 3 provides an overview of the literature to-date.
Most series included large or giant paraclinoid ICA aneurysms occluded with clip ligation after
balloon catheter placement in the ICA [69–71]. Intra-luminal pressure was decreased through the
additional placement of a temporary clip distal to the aneurysm on the posterior communicating artery
to reduce collateral blood flow, as well as the application of the retrograde decompression-suction
method in the ICA [69,71,72]. In these series, endovascular TBO eliminated the need for cervical ICA
dissection [68,69]. A review of the literature found a total of 188 aneurysms clipped with TBO. The largest
series, published by Fulkerson et al [73]. included 63 ophthalmic artery aneurysms. The description
of TBO in posterior circulation aneurysms, however, is less common with a total of only 20 cases.
Bailes et al. published the first series of TBO use in multiple basilar artery aneurysms [74]. Apart from
the recent study, eight other series have used TBO only for successful clipping [64,65,68,70,74–77].
Balloon placement in the aneurysm orifice or neck has only been described in two case series [65,77]
and was otherwise performed in the proximal parent vessel. TBO duration ranged from 1.5–3 min for
each balloon inflation and a total maximum of 50 min [43,63–65,68,71,75,77–81].
The overall reported complication rate for TBO is very low at 1.7–3.7% [72]. TBO procedure-related
thromboembolic events occurred in five patients (2.6%). This risk is increased in cases with pronounced
vessel wall sclerosis or prolonged temporary occlusion. One intraoperative balloon rupture and balloon
exchange led to a thrombus in the M1 segment, with subsequent intraoperative embolectomy and
postoperative transient hemiparesis. Symptoms such as dysphasia and hemiparesis were transient
in all other cases except one major MCA infarct, which lead to the death of the patient [71,80–82].
Further TBO-related complications included: ICA intima dissection with ICA occlusion at the neck
requiring medical treatment only (recovery was complete after four days) [81], as well as increases in
vasospasms due to mechanical wall stimulation with transient hemiparesis [77].
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Thromboembolic events may be reduced by limiting TBO duration and using double-lumen
balloon systems that allow for maintaining continuous heparinized saline catheter flush. In thrombosed
aneurysms or patients with severe atherosclerosis, the risk for thromboembolism might be increased.
No complications occurred in our series that had a mean TBO time of 10 min. Several series suggested
multiple short inflation times of 1.5–5 min to reduce thromboembolic event rate [63,65,78]. Some studies
used a preoperative TBO test [83] to investigate the capacity of collateral support. In view of the
short TBO time in our series, it is questionable if this is needed. The advantage of performing a TBO
procedure in the hybrid OR is that control angiography is possible immediately after clip placement.
We performed 2D and 3D intraoperative angiography in the hybrid OR and confirmed aneurysm
occlusion in all cases. This standardized protocol can achieve better outcomes [84,85].
The main limitation of our study is the small sample size, as we chose to report on posterior
circulation aneurysms only.
5. Conclusions
Intraoperative endovascular TBO is a feasible, safe, and valuable procedure for surgical treatment
of complex posterior circulation aneurysm undergoing clipping. In addition, intraoperative DSA and
3D-DSA in the hOR was confirmed as a valuable tool for the evaluation of aneurysm occlusion and
possible aneurysm remnants.
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Abstract: Background: Biological processes that lead to aneurysm formation, growth and rupture
are insufficiently understood. Vessel wall inflammation and degeneration are suggested to be the
driving factors. In this study, we aimed to investigate the natural course of vital (non-decellularized)
and decellularized aneurysms in a rabbit sidewall and bifurcation model. Methods: Arterial pouches
were sutured end-to-side on the carotid artery of New Zealand White rabbits (vital [n = 6] or
decellularized [n = 6]), and into an end-to-side common carotid artery bifurcation (vital [n = 6] and
decellularized [n = 6]). Patency was confirmed by fluorescence angiography. After 28 days, all animals
underwent magnetic resonance and fluorescence angiography followed by aneurysm harvesting for
macroscopic and histological evaluation. Results: None of the aneurysms ruptured during follow-up.
All sidewall aneurysms thrombosed with histological inferior thrombus organization observed in
decellularized compared to vital aneurysms. In the bifurcation model, half of all decellularized
aneurysms thrombosed whereas the non-decellularized aneurysms remained patent with relevant
increase in size compared to baseline. Conclusions: Poor thrombus organization in decellularized
sidewall aneurysms confirmed the important role of mural cells in aneurysm healing after thrombus
formation. Several factors such as restriction by neck tissue, small dimensions and hemodynamics
may have prevented aneurysm growth despite pronounced inflammation in decellularized aneurysms.
In the bifurcation model, rarefication of mural cells did not increase the risk of aneurysm growth but
tendency to spontaneous thrombosis.
Keywords: aneurysm; decellularization; inflammation; rabbits; vessel wall
1. Introduction
In intracerebral aneurysms, the risk of growth and rupture is associated with larger aneurysm size,
larger aneurysm height to neck aspect ratio and irregular configuration of the aneurysm [1–3]. However,
the biological mechanisms of these morphological characteristics are poorly understood. There is a
growing body of evidence that chronic vessel wall inflammation and loss of aneurysm mural cells is a
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crucial factor in the pathogenesis of aneurysm growth and rupture [4–6]. Aneurysms with vital vessel
walls may be able to recruit smooth muscle cells that are able to organize thrombus, to build a neointima
and, by phenotype switch, to synthesize extracellular matrix. On the other hand, those aneurysms
with a rarefication of cells in their vessel wall seem to be unable to promote aneurysm healing after
intraluminal thrombosis. Instead, intra-aneurysmal thrombus may promote chronic inflammation,
further weakening of the vessel wall and finally leading to aneurysm growth and rupture [6,7].
This difference becomes fundamentally crucial with endovascular aneurysm treatments, which are
conceptually based on a biological healing process, rather than just mechanical flow obstruction [7–9].
The abovementioned putative pathophysiological mechanism was first observed in human
samples [10] and later confirmed in an experimental setting in rat saccular sidewall aneurysms [11].
Rabbits stand higher up in the translational chain than rats and allow for experimental creation of
complex, more physiological bifurcation aneurysms by means of rheology and hemodynamics [12,13].
Rabbit models are considered ideal for testing of novel endovascular devices, because the rabbit carotid
artery is accessible with endovascular devices of the same size as in humans. Therefore, this study
aims to investigate the natural course of vital and decellularized aneurysms in a rabbit sidewall and
bifurcation aneurysm model with an emphasis on aneurysm patency, growth and mural inflammation.
2. Materials and Methods
New Zealand white rabbits aged 4 months (weighing 3750 ± 293 g) received care in accordance
with institutional guidelines. The Committee for Animal Care of the Canton Bern, Switzerland (BE
108/16) approved the experiments. An a priori power analysis was performed, revealing n = 6 animals
per group needed to reach statistical significance with an estimation of 30% difference between groups.
Two animals served as pilots. All animals were randomly allocated to either vital or decellularized
aneurysm group. For each group, 6 aneurysms were created. For sidewall aneurysm creation, two
animals were used as tissue donors. Two aneurysms (one on each common carotid artery) were
created in one animal. For bifurcation aneurysms, only one aneurysm was created per animal. Graft
interpositions were taken from the same animal, with no need for additional donor animals.
2.1. Creation of Sidewall Aneurysms
Female rabbits were premedicated with an intramuscular injection of Ketamine HCL 30 mg/kg
(Ketalar, 50 mg/mL, Pfizer AG, Zürich Switzerland) and Xylazine 6 mg/kg (Xylapan 20 mg/mL). An
auricular vein was then catheterized and a continuous infusion of anesthesia solution (10mL Ketalar
and 1.6 mL Xylapan in 50 mL NaCl) was installed with a flow rate of 4–14 mL/h. Furthermore, Fentanyl
1 mg/kg (Fentanyl, Janssen-Cilag, Zug, Switzerland) was applied for analgesia. Animals breathed
spontaneously through an oxygen mask. During the operation, animals were located on a heating
panel and physiological variables such as heart rate, blood pressure and temperature were continuously
monitored. After local infiltration of the pectoral musculature with lidocaine (Lidocaine 1%, Streuli &
Co, Uznach, Switzerland), the common carotid artery was dissected on both sides and a previously
prepared donor graft (either vital or decellularized) was sutured in an end-to-side configuration, to
form a sidewall aneurysm. Nimodipine (Nimotop 0.2 mg/mL, Bayer, Leverkusen, Germany) was locally
applied to prevent for vasospasms. A fluorescence angiography was then performed [14,15], to ascertain
aneurysm perfusion and patency of the underlying vessel. Afterwards, incised tissues (musculature,
subcutaneous and skin) were readapted and closed. Postoperative analgesia was ascertained with
transdermal fentanyl application (12 μg/72 h). All animals received postoperative antibiotics by
intramuscular injection of terramycin (60 mg/kg), vitamin B12 (Novartis, Basel, Switzerland) 100 mcg
subcutaneous and prophylactic low-molecular weight heparin (250 units/kg) subcutaneous.
2.2. Creation of Bifurcation Aneurysm
Due to an internal periodic veterinarian re-evaluation of the standards, anesthesia protocols
were slightly adopted for bifurcation models. Premedication comprised subcutaneous application
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of Ketamine 20 mg/kg, Dexmedetomidine (Novartis, Basel, Switzerland) 100 mg/kg and Methadone
(Novartis, Basel, Switzerland) 0.3 mg/kg. Animals were then preoxygenated through a facial mask,
before installation of peripheral catheters in the auricular vein and in the contralateral auricular artery.
Then, propofol (1–5 mg/kg) (Novartis, Basel, Switzerland) and 0.2–1 mg/kg midazolam (Novartis,
Basel, Switzerland) were intravenously administered, followed by intubation with an endotracheal
tube (3 mm). Mode of the breathing system was chosen circle, able to be changed from ventilation
to spontaneous breathing anytime. A heating pad was continuously used to keep the animals warm
during the procedure. For monitoring, a continuous electrocardiogram, a rectal temperature probe and
a bispectral index were installed. Analgesia was ascertained by local subcutaneous infiltration with
ropivacaine (Novartis, Basel, Switzerland), followed by a continuous rate of infusion of 50 mcg/kg/min
lidocaine (Novartis, Basel, Switzerland) and fentanyl boli of 3–10 mcg/kg/h. Postoperatively, Meloxicam
0.5 mg/kg (Novartis, Basel, Switzerland), Vitamin B12 100 mcg (Novartis, Basel, Switzerland) and
Clamoxyl 20 mg/kg (Novartis, Basel, Switzerland) were administered subcutaneously. For the first three
days, low-molecular weight heparin (250 units/kg) and meloxicam were administered subcutaneously
(likewise methadone was administered, if an additive was needed). The detailed surgical technique for
creation of bifurcation aneurysms has been presented elsewhere [16]. Briefly, bifurcation aneurysms
were created by end-to-side anastomosis of the right common carotid artery to the left common carotid
artery and interposition of an arterial pouch, either vital or decellularized.
2.3. A Protocol for Decellularization
Untreated donor arterial grafts with a standardized length of 3–4 mm were taken from a segment
of the common carotid artery of a donor animal, ligated with a 6-0 suture on one end and immediately
reimplanted in a recipient animal or stored in phosphate buffered saline (PBS) at −4 ◦C for a maximum
of 3 days. All aneurysm pouches were measured, and photo documented on creation and again at
follow-up. For decellularization, a modified protocol of a previously described methodology was
performed [11,17]: First, grafts were frozen in PBS at −4 ◦C for several days. Later, they were thawed,
rinsed with distilled water and incubated in 1% sodium dodecyl sulphate (SDS) for 6 h at room
temperature. The SDS-treated grafts were then washed with gentle shaking and refrozen and kept in
PBS at −4 ◦C until reimplantation. To establish these modifications of the original protocol, various
SDS concentration (0.1% and 1%) and several time spans for decellularization (6 h, 9 h,12 h, 15 h and
2 h, 4 h, 6 h, 8 h, respectively) were assessed. All samples were histologically cut and stained with
4′,6-diamidino-2-phenylindole (DAPI) to count nuclei and with hematoxylin-eosin (HE), to assess
the integrity of the extracellular matrix such as elastic fibers. Cell nuclei were counted three times
for three randomly selected cuts, in each slice specifically for the following wall layers of the vessel:
endothelium, media and adventitia. Digital photographs of the microscopic images were taken and
analyzed while blinded to the treatment. Near-complete graft decellularization with extracellular
fibers still intact was documented after 6 h of 1% SDS treatment.
2.4. Outcome Measurements
After creation, sidewall aneurysms were followed with color coded duplex sonography (SonoSite
180 PLUS, SonoSite, Bothell, WA, USA) on post-operative day 1, day 3 and every 7 days thereof. After
a follow-up period of 28 days all animals underwent MRI with MR-angiography (MRA). Immediately
afterwards aneurysms were surgically re-exposed, and a fluorescence angiography was performed
before euthanasia with an overdose of thiopental (Esconarkon ad us. vet, Streuli & Co, Uznach,
Switzerland) and tissue harvesting. Aneurysms were macroscopically inspected and measured.
Aneurysm volume was calculated on the basis of a = length, b =width and l = height, with the formula
π(1.5(a + b) − √ab)(l − b) + (2/3 × π × ab2). Afterwards fixation in formalin (4% weight/volume
solution, J.T. Baker, Arnhem, The Netherlands) and embedding in paraffin for histological analysis
followed. Histological staining included HE, Masson–Goldner trichrome, smooth muscle actin, and
von Willebrand factor (F8) staining. Stained slices were digitalized (omnyx VL120, GE healthcare,
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Chicago, IL, USA) and evaluated with the JVS viewer (JVS view 1.2 full version, University of Tampere,
Finland). Histologic scoring was performed blinded to treatment allocation. A 4-scale grading
system (“none”, “mild”, “moderate”, “severe”) was applied to characterize histology, according to the
previously presented neointima score [11].
2.5. Statistics
Data were analyzed and visualized using Graph Pad Prism statistical software 8.3.1 for Windows
(GraphPad Software, Sand Diego, CA, USA). Unpaired Mann–Whitney test was used to calculate
differences between vital and decellularized aneurysms according to histological analysis with
non-parametric values. Values are presented as median with interquartile range and arbitrary units 0–3
representing categories (“none”, “mild”, “moderate”, “severe”) according to the neointima score [11].
A p-value of <0.05 was considered statistically significant and a p-value of <0.001 was considered
highly significant.
3. Results
During the study period, no aneurysm ruptured. All sidewall aneurysms (vital and decellularized)
thrombosed spontaneously during follow-up. Histologically, inferior thrombus organization was
observed in decellularized aneurysms when compared to healing characteristics in vital aneurysms.
In the arterial pouch bifurcation model, three out of six aneurysms with decellularized walls thrombosed
spontaneously whereas all vital aneurysms (six out of six) stayed patent, with relevant growth pattern
in two cases.
3.1. Study and Animal Characteristics
Totally, 22 New Zealand white rabbits were included in this study, weighting 3750 ± 293 g.
No animals had to be excluded due to severe comorbidities and no animal died prematurely before
planed euthanasia on follow-up day 28. See Figure 1 for an overview of the experimental setting.
For histological evaluation one vital aneurysm in the sidewall constellation and one decellularized
aneurysm in the bifurcation constellation was excluded from the final analysis due to insufficient
detection of the relevant structures after histologic processing of these heavily scarred aneurysms.
 
Figure 1. Study design and animal numbers. No animals had to be excluded prematurely for morbidity
or mortality.
3.2. Aneurysm Patency
All sidewall aneurysms showed initial flow upon creation but thrombosed within the first two
weeks after creation and were not detectable thereafter with either ultrasound or MR angiography.
Intraoperative fluorescence angiography confirmed flow obliteration in all these cases. Calculated
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volume, based on the measured aneurysm size, was significantly smaller for scarred aneurysms at
follow-up (7.55 ± 2.73 mm3) than they were at creation (11.27 ± 3.27 mm3), p = 0.0033 (Figure 2).
Figure 2. Aneurysm size at baseline and follow-up. Relevant growth pattern was observed in 2 cases
of vital bifurcation aneurysms, whereas all the sidewall aneurysms thrombosed spontaneously.
In bifurcation aneurysms, only three out of six aneurysms with decellularized walls thrombosed
and all of these with vital vessel walls remained patent until follow-up (exemplary illustration in
Figure 3).
Figure 3. Exemplary illustration of a patent vital bifurcation aneurysm. The operative situs through
the operative microscope (a) and the corresponding fluorescence angiography (b) visualize blood flow
in both, the aneurysm and the parent artery at the time of aneurysm creation. One-month patency is
confirmed by magnetic resonance angiography (c).
Furthermore, these aneurysms showed a pattern of growth from (6.48 ± 1.81 mm3) on creation to
(19.48 mm3 ± 6.40 mm3) follow-up (p = 0.037)
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3.3. Histological Analyses
Overall, there was more inflammation in decellularized aneurysms than in those with vital vessel
walls. In sidewall aneurysms, this was reflected by significantly more neutrophil invasion in the
thrombus in decellularized than in vital aneurysms (p = 0.0065) (Figure 4).
 
Figure 4. Exemplary histology on a 16-fold digital zoom of a decellularized (a) and a vital (b) aneurysm
in sidewall constellation. The degenerated aneurysm wall (# in a) contains predominantly extracellular
matrix fibres only. By contrast, the vital aneurysm wall (# in b) is marked by a high cell density.
Inside the thrombus (*) of decellularized aneurysms (a), excessive neutrophil infiltration was observed.
In (b), hardly any neutrophils are visible and derivates of myofibroblast have organized the former
intraluminal hematoma into mature thrombus and scare tissue. Furthermore, a thick and consistent
neointima (+) separates the former aneurysm cavity from the lumen of the parent artery (§) (similar but
no visible in (a)).
In bifurcation aneurysm, there were significantly more inflammatory cells (neutrophils) in the
wall of decellularized aneurysms compared to vital aneurysms (p = 0.013). Periadventitional fibrosis
was higher in vital aneurysms than in decellularized ones (p = 0.013). All histological characteristics
are summarized in Figure 5.
Figure 5. Cont.
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Figure 5. Detailed histological findings for all analyzed features. In both models, aneurysm wall
cellularity was significantly lower in decellularized aneurysms than in vital aneurysms, confirming
a successful experimental decellularization (a). Spontaneous thrombosis and neointima formation
(b) were strong in the sidewall constellation, but not so in the bifurcation model. In the bifurcation
model, aneurysm wall inflammation was significantly more pronounced in decellularized aneurysms
when compared with vital aneurysms (c). However, there was no difference in terms of aneurysm wall
inflammation in the sidewall model. On the other hand, there were significantly more inflammation
cells, i.e., neutrophils in the thrombus of decellularized sidewall aneurysms, a difference not as distinctly
observed in the bifurcation constellation (d). In turn, periadventitial fibrosis was significantly higher in
vital than in decellularized bifurcation aneurysms, but not in sidewall aneurysms (e). There were no
relevant differences for periadventitial inflammation (f), aneurysm wall dissection (g) or aneurysm wall
hematoma (h) between different wall conditions for either aneurysm model. A 4-scale grading system
0 = none, 1 = mild, 2 = moderate, 3 = severe was applied to characterize histology [11]. *: p < 0.05,
** p < 0.001.
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4. Discussion
The results of this study demonstrate that all arterial pouch (decellularized and non-decellularized)
sidewall aneurysms thrombose spontaneously during follow-up without increase in size. Poor
thrombus organization in decellularized sidewall aneurysms confirms the important role of mural
cells in aneurysm healing. In the bifurcation aneurysm model, removal of mural cells did not increase
the risk of aneurysm growth.
In our experiments, all sidewall aneurysms thrombosed spontaneously without any treatment.
This is opposed to the natural course of saccular sidewall aneurysms which were sutured as standardized
arterial pouches on the abdominal aorta in a rat model [18]. In that model the authors found a clear
pattern of growth in decellularized aneurysms [11]. We hypothesize that the pressure of surrounding
muscular tissues in the rabbit neck may counteract the artificially created saccular aneurysms from
growth. Furthermore, the base dimensions of these aneurysms are given by the diameter of the carotid
artery of the donor animal. This size was usually smaller (approximately 1–1.5 mm) than in a rat aorta
(2–3 mm). Together with the different hemodynamics between the rat aorta and the rabbit carotid
artery, these aneurysms may have been simply too small for a sufficient perfusion, particularly since
the relatively thick and muscular arterial walls may have a tendency to self-contract or increased
fibrosis after transplantation. Ding et al. found a patency rate of 95% after 3 weeks in venous pouch
sidewall aneurysms on rabbit carotids [19].
In order to overcome these limitation factors, as a next step we repeated the series with
non-decellularized and decellularized arterial pouch aneurysms in a hemodynamically more
challenging bifurcation constellation. Previous experiments demonstrated in various species (rats,
rabbits and dogs) that spontaneous thrombosis occurs less frequently in bifurcation than sidewall
venous pouch aneurysms [20–22]. In contrast to these earlier findings, however, all decellularized
arterial pouch aneurysms thrombosed even in the setting of an artificial bifurcation. Most previous
studies with degenerated vessel walls used elastase eradication of the cells [23–26]. Sodium dodecyl
sulfate (SDS) is a detergent that destroys cells but leaves extracellular matrix intact. Its use for
experimental decellularization worked well in a previously established rat model, where decellularized
aneurysms have been shown to grow over time and eventually rupture, in contrast to aneurysms
with vital vessel walls [6,9,11]. However, the completely decellularized graft (including eradication
of endothelial cells) after SDS treatment may exhibit prothrombogenic properties. This may be an
explanation for the finding of high rate of thrombosed decellularized bifurcation aneurysms. The
growing pattern of bifurcation aneurysms with vital vessel walls indicates that the hemodynamic
constellation (in a vessel bifurcation) is an important factor for aneurysm enlargement/growth.
When comparing vital and decellularized aneurysms histologically, there was a clear pattern
of more pronounced inflammation in decellularized aneurysms for both sidewall and bifurcation
aneurysms. This is in line with previous findings [27–29]. For aneurysm healing, intraluminal thrombus
needs to undergo gradual organization into a mature thrombus and a neointima needs to form. This
process is mediated by smooth muscle cells and myofibroblasts, which migrate into the thrombus,
presumably originating in the vessel wall. If there is a substantial diminution in the pool of these cells
(i.e., after decellularization) the intraluminal thrombus will undergo cycles of lysis and re-thrombosis
instead of scarification [6,11]. This instable thrombus formation causes local inflammatory reactions
which promotes further vessel wall weakening.
In summary, there was more pronounced inflammation in decellularized aneurysm than in
those with vital walls. However, decellularized aneurysms did not show any pattern of growth or
rupture, neither in a sidewall nor in a bifurcation constellation. Therefore, the presented aneurysm
models need further refinements to allow for meaningful experiments with a translational focus.
Further experiments should use other degrading substances like elastase, test anti-platelet medications
to prevent spontaneous thrombus formation, or relocation of the experimental aneurysms into the
abdominal cavity to allow for more unrestricted growth. However, with all these issues addressed, still
no animal model ever will perfectly match all aspects of the human condition of the disease [30,31].
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For instance, there are relevant differences in thrombus formation and endothelial cell coverage
between rabbits and humans. In addition, we used healthy arteries in which cells but not the
extracellular matrix was destroyed to form aneurysms. However, the elastin content of real aneurysms
is inferior to that of healthy arteries [32]. Furthermore, the aneurysm angioarchitecture influences
hemodynamic characteristics, and with that the rate of spontaneous thrombosis. Despite all efforts
made to standardize aneurysm dimensions and geometry (the latter specifically for either sidewall
or bifurcation constellation), we could not avoid differences of few millimeters in size of the vessel
pouches and thus in hemodynamics. Further limitations include the relatively small sample size
of n = 6 animals per group. Lastly, a longer follow-up than 28 days would probably be better to
characterize hemodynamic-induced changes in the bifurcation constellation.
5. Conclusions
The results of poor thrombus organization in decellularized rabbit arterial sidewall aneurysms
confirm the important role of mural cells in aneurysm healing after intraluminal thrombus formation.
Several factors such as restriction by neck tissue, small dimensions and hemodynamics may have
prevented aneurysm growth despite pronounced inflammation in decellularized aneurysms. Even in
the bifurcation aneurysm model, removal of mural cells did not increase the risk for aneurysm growth
but resulted in a higher rate of spontaneous thrombosis. Future studies should examine the role of less
thrombogenic degenerated aneurysm wall pouches in a rabbit artificial bifurcation model.
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Abstract: Background: The inflammatory pathway in cerebrospinal fluid (CSF) leads to delayed
cerebral vasospasm (DCVS) and delayed cerebral ischemia (DCI) after subarachnoid hemorrhage
(SAH). The role of IL-1α has never been evaluated in a rabbit SAH model. The aim of our study is
to analyze systemic and CSF changes of IL-1α, and to evaluate potential associations with the onset
of DCVS in a rabbit closed cranium SAH model. Methods: 17 New Zealand white rabbits were
randomized into two groups, SAH (n = 12) and sham (n = 5). In the first group, SAH was induced
by extracranial-intracranial shunting from the subclavian artery into the cerebral cistern of magna
under intracranial pressure (ICP) monitoring. The sham group served as a control. The CSF and blood
samples for IL-1α measurement were taken at day zero before SAH induction and at day three. Results:
There was a significant increase of ICP (p = 0.00009) and a decrease of cerebral perfusion pressure
(CPP) (p = 0.00089) during SAH induction. At follow up, there was a significant increase of systemic
IL-1α in the SAH as compared with the sham group (p = 0.042). There was no statistically significant
difference in the CSF values in both groups. The CSF IL-1α values showed a correlation trend of DCVS.
Conclusions: Systemic IL-1α levels are elevated after SAH induction in a rabbit SAH model.
Keywords: subarachnoid hemorrhage; IL-1α; inflammation; animal model
1. Introduction
Delayed cerebral vasospasm (DCVS) and delayed cerebral ischemia (DCI) are severe complications
of subarachnoid hemorrhage (SAH). The inflammatory pathway due to blood hemolysis in cerebrospinal
fluid (CSF) has been recognized to be one of the leading factors causing DCVS and DCI. Different
cytokines and interleukins have been described as mediators of the inflammation cascade initiated
by blood products in the subarachnoid space, leading to DCVS and DCI [1–4]. Interleukin-1 (IL-1)
is a family of cytokines which induces a group of different cytokines and the expression of integrins
on leukocytes and endothelial cells mediating the inflammatory response [5–7]. IL-1 is produced in
different immune cells such as macrophages, lymphocytes, and microglia [8,9]. Despite IL-1 being
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typically linked to inflammation, it has also been associated with different functions such as insulin
secretion, fever induction, and neuronal phenotype development [10–14]. IL-1 has been described to
be a key mediator of neuronal injury after acute brain injury [15,16]. Moreover, it usually upregulates
the expression of interleukin-6 (IL-6), which triggers local inflammation and activation of the systemic
acute phase response. IL-1 stimulates the release of IL-6 from mast cells [17], which have been described
to be present in the aneurysm wall of SAH patients and the muscular layer of cerebral arteries [18,19].
The IL-6 concentrations are elevated in the cerebrospinal fluid (CSF) in animal models of SAH and
in patients suffering SAH. Moreover, high concentrations of CSF IL-6 correspond to worse clinical
outcomes in patients affected by SAH [1,3].
IL-1α and IL-1β are the most known interleukins subtypes in the IL-1 family and both are
proinflammatory and bind at the same receptor, the type I IL-1 receptor (IL-1RI). The initiated signaling
cascade results in the expression of inflammatory genes [5,6,20]. IL-1α differs mainly from IL-1β in
primary structure. IL-1α, in contrast to IL-1β, appears to have bioactivity while in the form of an intact
pro-cytokine precursor on the cell surface and intracellularly [21]. The IL-1 receptor antagonist (IL-1Ra)
blocks the signaling at the receptor, inhibiting the inflammatory effects of IL-1α and IL-1β [22,23].
IL-1α has an emerging importance in the initiation and maintenance of inflammation in different
human diseases and the initiation of the sterile inflammatory response. In ischemic strokes, IL-1α has
been described to be expressed early in areas of focal neuronal injury after ischemic injury. In addition,
it is chronically elevated in the brain after an experimental stroke, suggesting that it is present during
post-stroke angiogenic periods. Moreover, IL-1α not only precedes the expression of IL-1β and IL-6,
but it has also been described to be more potent in stimulating the expression of IL-6 [24–26].
Considering that to date no medical treatment has been shown to properly prevent the onset
of DCVS and DCI after SAH, the outcome of patients affected by DCVS and DCI after SAH remains
very poor. As previously described, the inflammation reaction initiated in early brain injury phase
after SAH is highly involved in the development of DCVS and DCI [1,3,18,27]. IL-1α is one of the key
player and the earliest interleukins released during the sterile inflammation cascade [24]. A better
understanding of this interleukin in the inflammation cascade after SAH could be essential for the
development of future target therapies to prevent DCVS and DCI in patients affected by SAH.
With this study, we aimed to evaluate the levels of systemic and CSF IL-1α in an established
extracranial intracranial closed rabbit SAH model and to analyze if there are any correlations with DCVS.
2. Materials and Methods
2.1. Animals, Study Design, and Anesthesia
As a subproject of an ongoing study, a total of 17 female New Zealand white rabbits (3.1–4.1 kg
body weight, 16 weeks old, Charles River, Sulzfeld, Germany) were previously randomly allocated into
two different groups using a web-based randomization system [28], i.e., the SAH group (n = 12) and in
the sham group (n = 5). After the clinical examination, general anesthesia was induced in all rabbits
with a mixture of subcutaneous ketamine (Narketan 100 mg/mL, Vetoquinol AG, Bern, Switzerland)
(30 mg/kg) and xylazine (6 mg/kg, Xylapan, 20 mg/mL, Vetoquinol AG, Bern, Switzerland). After 15 min
under administration of 2–4 L of O2 through a facial mask, two 22 G intravenous cannulae were inserted
in the marginal auricular vein and into the auricular artery, respectively. Perincisional ropivacaine
1% (Sintetica S.A., Mendrisio, Switzerland) was infiltrated into the axillary region (access for the
subclavian artery). A supraglottic device was introduced and general anesthesia maintained with
isoflurane in oxygen targeting an EtIso of 1.3%. Spontaneous ventilation was allowed. Ringer lactate
(4–10 mL/kg/h) was infused through the vein access. Continuous monitoring of heart rate, respiratory
rate, oxygen arterial saturation, capnography, invasive blood pressure, non-invasive blood pressure
(Doppler technique), esophageal temperature, as well as inspired and expired fraction of gases (air,
CO2 and isoflurane) was provided. During the procedure, at least 1 blood gas was analyzed.
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Additional boluses of fentanyl (Fentanyl Syntetica 0.5 mg/10 mL, Sintetica S.A., Mendrisio,
Switzerland) were provided (3–10 mcg/kg IV) if nociception was deemed insufficient. Nociception was
continuously assessed through cardiovascular monitoring and at intervals of 5 min through stimulation
of pedal reflex (toe pinch). Hypothermia was prevented using a warming mattress and hypotension
(MAP less than 60 mmHg) was addressed with the use of noradrenaline titrated to effect. Postoperative
analgesia was provided with a fentanyl patch (12 mcg/h; Durogesic Matrix 12 μg/h, Janssen-Cilag
AG, Schaffausen, Switzerland) put on the outer ears. The animals were carefully observed during the
recovery phase. Oxygen supplementation and fluid therapy were provided until sternal recumbency
was achieved. Neurological status was assessed at 6, 12, 24, 48, and 72 h post SAH, according to a
four-point grading system, as previously described [29].
2.2. Digital Subtraction Angiography and SAH Induction
Detailed protocols for surgery and angiography have been previously described elsewhere [30–32].
Digital subtraction angiography (DSA) was performed under general anesthesia at day 0 prior to
SAH and on day 3. The rabbits’ subclavian artery was prepared and cannulated with a 5.5 French
catheter (Silicone Catheter STH-C040, Connectors Verbindungstechink AG, Tagelswangen, Switzerland).
The catheter tip was advanced to the origin of the vertebral artery. Intraarterial bolus injection of
contrast dye followed (0.6 mL/kg Iopamidol, Iopamiro, Bracoo Suisse, Mendrisio, Switzerland). Images
of the basilar artery were obtained using a rapid sequential angiographic technique (DFP 2000A,
Toshiba, Tokyo, Japan). The same procedure was performed at day 3 for follow up. The caliber of the
basilar artery (BA) was measured, as previously described (the midpoint of the basilar artery, and 0.5 cm
above and below), in a blinded manner using ImageJ (National Institutes of Health, Bethesda, MD,
USA) [1,33]. To assess the degree of DCVS, the relative change between baseline and follow up was
compared [1,30,34]. Following baseline DSA on day 0, either induction of SAH or sham procedure was
performed, as described earlier [30–32,35,36]. In all animals, intracranial pressure (ICP), arterial blood
pressure, and respiration rate were continuously monitored. An ICP probe (Codman Disposable ICP
Kit, Spreitenbach, Switzerland) was inserted through a right frontal osteotomy [37]. Arterial blood gas
analysis was performed prior to angiography (ABL 725, Radiometer, Copenhagen, Denmark). In prone
position, a 27 G spinal access needle was inserted into the cisterna magna. In animals assigned to the
SAH, the needle was connected to the catheterized subclavian artery to induce a hemorrhage [30,31].
Sham-operated animals underwent puncture of the cisterna magna, CSF sampling (1.5 mL), and CSF
replacement with 1.5 mL artificial CSF (ACSF, Tocris Bioscience, Bristol, UK).
2.3. Blood and CSF Samples Analysis
CSF and blood samples were taken at day 0 and day 3. At day 0, 1.5 mL CSF was aspirated after
puncture. The blood samples were collected together with the blood gas analysis using EDTA-coated
tubes. The samples were centrifuged with 1500× g for 15 min at 4 ◦C. The supernatant was segregated
and stored at −80 ◦C until measurement. For IL-1α quantification, a specific IL-1α enzyme-linked
immunosorbent assay (ELISA) kit was used (Cayman Chemical, 1180 E. Ellsworth Rd, Ann Arbor, MI,
USA). ELISA was performed according to the manufacturers’ protocol. Euthanasia was performed on
day 3 by injection of 40 mg/kg sodium thiopental (Pentothal, Ospedalia, Hünenberg, Switzerland).
2.4. Statistical Analysis
Data were analyzed and visualized using IBM SPSS statistical software version 21.0 (IBM Corp.,
New York, NY, USA). Continuous values were given as mean ± SD, if not otherwise indicated.
The comparison of baseline and follow up was compared by the Wilcoxson signed rank test
(nonparametric, repeated measures). The differences between the normally distributed IL-1α measures
and baseline values of two groups and the neurological scores were analyzed by Student’s t-test.
A p-value < 0.05 was regarded as statistically significant. Correlations were calculated by the Pearson’s
correlation test.
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2.5. Ethic Approval
The study was performed in accordance with the local guidelines for the care and use of
experimental animals. The project was performed according to the Animal Research: Reporting of
In Vivo Experiments (ARRIVE) guidelines [38] and was performed in accordance with the National
Institutes of Health Guidelines for the care and use of experimental animals and with the approval
of the Animal Care Committee of the Canton Bern, Switzerland (Approval Nr. BE58/17). A power
analysis was not applicable because of the exploratory nature of the study and because it was part of a
subproject of a larger study.
3. Results
3.1. Physiological Parameters, ICP Time Course, and SAH and Clinical Scores
A total of 14 (10 in the SAH and four in the sham group) out of 17 rabbits reached the primary
endpoint. One rabbit was prematurely excluded after it died before the start of the group-specific
procedures. In two rabbits, premature euthanasia was performed due to a severe postoperative
neurological deficit after SAH induction. Arterial blood gas analysis was invalid for one animal in each
of the SAH and sham operated group during follow up. There were no complications either related to
wound healing, cerebrospinal fluid leakage, or infections along the frontal osteotomy sites, subclavian
skin incision, or nuchal cisterna injection point.
Arterial blood gas values and basic physiological parameters were within a normal range and
there was no significant difference between the groups at baseline and follow up, except for potassium
levels which were significantly higher at follow up in the sham operated group (Table 1).
All animals in the SAH group showed a significantly marked ICP increase during SAH induction
from baseline to peak (p = 0.00009), with a corresponding decrease of cerebral perfusion pressure (CPP)
(p = 0.00089) (Figure 1, panel left). During SAH induction, there were no significant changes of middle
arterial pressure (MAP) and respiratory rate (RR) between the baseline and the peak. There was a trend
of worse neurological outcomes during the postsurgical period in the SAH group without significant
differences, p = 0.27 (Figure 1, panel right).
Figure 1. Pathophysiological characteristics of SAH animals (left panel) representing the changes of
intracranial pressure (ICP), cerebral perfusion pressure (CPP), respiratory rate, and middle arterial
pressure (MAP) at baseline (before SAH induction) and at peak (after SAH induction). Note, between
baseline and peak there was a statistically significant increase of ICP and decrease of CPP, respectively.
Data are presented as mean ± SD, *: p < 0.05. The right panel shows the neuroscores of the rabbits
assessed at 6, 12, 24, 48, and 72 h after the surgical interventions. The SAH animals showed a tendency
of worse neurological scores as compared to rabbits in the sham group (p = 0.27).
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All surviving rabbits in the SAH group demonstrated extensive coagulated diffuse subarachnoid
blood which resulted in moderate grades of SAH with a mean bleeding sum score [34] of 5.9 (±2.1) in
the SAH group as compared to none in the sham group (p = 0.00002).
Table 1. Baseline and follow-up analyses for the subarachnoid hemorrhage (SAH) and sham groups.
Parameters SAH Group (n = 10) Sham Group (n = 4) p-Value
Baseline
pH 7.3 (±0.1) 7.3 (±0.1) 0.310
pCO2 (mmHg) 77.1 (±12.5) 70.5 (±14.5) 0.215
pO2 (mmHg) 340.5 (±95.2) 308 (±150.6) 0.330
HCO2-mmol/L 28.9 (±7.1) 30.0 (±0.6) 0.325
BE mmol/L 10.8 (±5.9) 9.1 (±2.9) 0.301
SO2% 99.8 (±0.5) 99.5 (±0.7) 0.268
ctHb (g/dL) 12.3 (±5.3) 12.5 (±0.1) 0.323
Na+ mmol/L 143.3 (±2.2) 142 (±2.2) 0.164
K+ mmol/L 3.5 (±0.3) 3.47 (±2.2) 0.401
Ca2+ mmol/L 1.6 (±0.1) 1.5 (±0.1) 0.187
Glu mmol/L 15.8 (±3.4) 15.7 (±1.1) 0.487
Lac mmol/L 0.5 (±0.3) 0.5 (±0.1) 0.371
Heart rate/min 187.6 (±18.6) 175.7 (±3.8) 0.223
Middle Arterial Pressure 54.6 (±4.6) 63.7 (±0.3) 0.082
Weight Kg 3.73 (±0.3) 3.53 (±0.2) 0.183
Follow up SAH Group (n = 9) Sham Group (n = 3) p-Value
pH 7.3 (±0.1) 7.3 (±0.1) 0.349
pCO2 (mmHg) 70 (±14.3) 68.9 (±14.7) 0.457
pO2 (mmHg) 351 (±27.8) 431.3 (±29) 0.078
HCO2-mmol/L 13.2 (±6.2) 22.5 (±7.2) 0.138
BE mmol/L 7.3 (±7.2) 14 (±7.3) 0.186
SO2% 99.2 (±0.8) 99.5 (±0.7) 0.338
ctHb (g/dL) 10.8 (±0.8) 10.8 (±0.4) 0.50
Na+ mmol/L 142.7 (±3.8) 143 (±3.5) 0.435
K+ mmol/L 3.5 (±1.7) 3.9 (±1.5) 0.006
Ca2+ mmol/L 1.5 (±0.1) 1.5 (±0.1) 0.449
Glu mmol/L 18.8 (±4.1) 18.6 (±0.4) 0.428
Lac mmol/L 0.6 (±0.1) 0.6 (±0.2) 0.415
Heart rate/min 177.5 (±20.2) 184.5 (±7.5) 0.371
Middle Arterial Pressure 53 (±12.7) 57 (±12.7) 0.399
Weight Kg 3.52 (±0.4) 3.35 (±0.1) 0.07
Baseline and follow-up arterial blood gas analyses, middle arterial pressure, and weight in the SAH and sham
groups (Legend: BE, base Excess; ctHb, concentration of hemoglobin; Glu, glucose, and Lac, lactate). Data are
presented as mean ± SD.
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3.2. Angiographic Delayed Cerebral Vasospasm
At day zero, the baseline angiography in the SAH group showed a mean BA diameter of
310 (±50) μm. At follow up, measurements showed a significantly decreased diameter with a mean of
220 (±60) μm, p = 0.0001. The sham group showed a mean BA diameter of 410 (±60) μm at baseline
and 450 (±70) μm at follow up (p = 0.446), Figure 2.
Figure 2. Left: Angiographic mean basilar artery diameter in μm at baseline and follow up. The mean
basilar artery diameter decreased significantly at follow up in the SAH group. Data are presented as
mean ± SD, *: p < 0.05. Right: DSA at baseline (BL) and follow up (FU) demonstrating decrease of
caliber size at FU. White arrows: Point of measurement of basilar artery caliber showing decrease of
size of the basilar artery at FU.
3.3. CSF and Systemic IL-1α Levels
Notably, overall CSF IL-1α values were significantly higher than serum IL-1α values (p < 0.0001).
Therefore, we measured CSF IL-1α levels in the range of 5–25 pcg/mL in the CSF while levels in
serum were below 1 pcg/mL (Figure 3). In the SAH group, there was a trend of higher CSF IL-1α
levels at baseline and follow up as compared with the sham group without statistical significance
(Figure 3). In the serum, there was a trend of increasing IL-1α levels between baseline and follow up
in the SAH group. When comparing the follow-up values in the sham and SAH groups there was a
significant increase of systemic IL-1α in the SAH group as compared with the sham group (p = 0.042).
The CSF-IL-1α values showed a trend of a negative correlation (Pearson’s r = −0.25, p = 0.410) with the
angiographic diameter of the basilar artery. No significant correlation between serum IL-1α values and
DCVS could be found (Pearson’s r = −0.03, p = 0.856).
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Figure 3. Mean baseline and follow-up IL-1α cerebrospinal fluid (CSF) and serum levels in pcg/mL.
Note that the overall CSF IL-1α values were significantly higher as compared to the serum IL-1α levels.
Moreover, the serum levels at follow up were significantly higher in the SAH group as compared to the
sham group. Data are presented as mean ± SD, *: p < 0.05.
4. Discussion
The results of this study demonstrated that SAH was well induced with a significant increase of ICP
and a decrease of CPP. DCVS was significantly present in the SAH group. The CSF IL-1α values were
overall significantly higher than serum IL-1α values. Moreover, at follow up, the SAH group showed a
significantly higher level of IL-1α in serum. A correlation trend between CSF IL-1α and DCVS was found.
Currently, there are neither prophylactic nor therapeutic approaches with convincing efficacy for
the treatment and prevention of DCVS and DCI after SAH. Despite various studies confirming the
importance of inflammation in the pathophysiology of DCVS and DCI after SAH [1,3,4,23], the clear
pathophysiology of the latter remains obscure. This is evident in the role of the different cytokines
in the inflammation process and the related effects on neuronal cell death and on endothelial cells,
which remain unclear. With this experimental study, we aimed to analyze the behavior of IL-1α in a
rabbit closed cranium SAH model. The systemic and CSF IL-1α changes have never been described in
a rabbit closed cranium SAH model.
In an ischemic stroke rat model, IL-1α, but not IL-1β, was expressed early on microglia-like cells in
the ischemic hemisphere [24,26]. Moreover, IL-1α expression was closely associated with areas of focal
blood–brain barrier breakdown and neuronal death, mostly near the penumbra surrounding the infarct,
and therefore suggests that IL-1α is the major form of IL-1 contributing to inflammation early after cerebral
ischemia [26]. In the context of SAH, a rat SAH model showed that haem induced the expression of
IL-1α, produced by microglia and macrophages in the central nervous system, was present early after SAH
throughout the brain [23–27,39]. Moreover pharmaceutically synthetized IL-1 Ra showed already promising
anti-inflammatory effects in clinical trials of acute stroke and SAH [40,41]. Phase I and phase II clinical
randomized trial studies showed that a reduction of IL-6 in serum and CSF and C-reactive protein in a SAH
patient treated with an IL-1Ra, however, these studies were not sufficiently powered to analyze the clinical
outcome of the patients [41,42]. Our results in this study showed that SAH was well simulated in all the
rabbits in the SAH group with a significant increase of ICP and a decrease of CPP, and with a relevant
presence of blood in the basal cistern and a significant presence of DCVS at follow up. These results are
concordant with our previous studies, confirming the efficacy of the rabbit closed cranium SAH model
simulating an aneurysmal SAH [1,30,31].
A correlation trend of CSF IL-1α, but not for serum IL-1α, with DCVS was found. Moreover,
the level of systemic IL-1α were significantly higher at follow up in the SAH as compared with the
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sham group. The overall CSF IL-1α values were found to be higher than the serum values in both
groups. This might be explained by a compartmental reaction in the CSF, with IL-1α release, possibly
caused either by the surgical procedure itself or due to the generated SAH. Due to the compartmental
inflammation reaction after SAH, CSF IL-1α might be more related to the development of DCVS than
the serum IL-1α values (especially considering the higher levels of IL-1α in CSF than serum). The fact
that serum IL-1α were higher in the SAH group at follow up, without showing a correlation with
DCVS, might reflect the compartmental inflammation reaction happening in the CNS.
The results of this study were somewhat inconclusive, especially considering that we did not find
any significant CSF increases of IL-1α in the SAH group between baseline and follow up, but only a
correlation trend for DCVS. Those results might possibly be explained by the rather small sample size
and the lack of power of the study, as this data were extrapolated from one larger study. We should also
consider that IL-1α is a generic inflammation cytokine at the top of the inflammation cascade and that
other cytokines, like IL-6 which triggers local inflammation and activation of the systemic acute phase
response, might play an ever more specific role in the development of DCVS and DCI, as previously
described [1,3,4]. Moreover, ELISA quantitative analysis of IL-1α were performed at day zero and
day three after induction of SAH. Considering that IL-1α is an early expressed cytokine, possible
measurement at day one and day two after SAH induction would have resulted in different values.
Further experimental and clinical studies are surely warranted to better understand the behavior of
IL-1α in the pathophysiology of DCVS and DCI and its relationship with neuronal cell death and
interaction with other cytokines.
5. Conclusions
CSF IL-1α shows that a correlation trend with DCVS and systemic IL-1α is significantly elevated
after SAH induction in a rabbit SAH model. IL-1α plays an important role at the beginning of the
inflammation cascade in a rabbit closed cranium SAH model.
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Abstract: Background: Delayed cerebral vasospasm (DCVS) due to aneurysmal subarachnoid
hemorrhage (aSAH) and its sequela, delayed cerebral ischemia (DCI), are associated with poor
functional outcome. Endothelin-1 (ET-1) is known to play a major role in mediating cerebral
vasoconstriction. Angiotensin-II-type-1-receptor antagonists such as Sartans may have a beneficial
effect after aSAH by reducing DCVS due to crosstalk with the endothelin system. In this review,
we discuss the role of Sartans in the treatment of stroke and their potential impact in aSAH. Methods:
We conducted a literature research of the MEDLINE PubMed database in accordance with PRISMA
criteria on articles published between 1980 to 2019 reviewing: “Sartans AND ischemic stroke”.
Of 227 studies, 64 preclinical and 19 clinical trials fulfilled the eligibility criteria. Results: There was
a positive effect of Sartans on ischemic stroke in both preclinical and clinical settings (attenuating
ischemic brain damage, reducing cerebral inflammation and infarct size, increasing cerebral blood
flow). In addition, Sartans reduced DCVS after aSAH in animal models by diminishing the effect of
ET-1 mediated vasoconstriction (including cerebral inflammation and cerebral epileptogenic activity
reduction, cerebral blood flow autoregulation restoration as well as pressure-dependent cerebral
vasoconstriction). Conclusion: Thus, Sartans might play a key role in the treatment of patients
with aSAH.
Keywords: aneurysmal subarachnoid hemorrhage; delayed cerebral vasospasm; ischemic stroke;
Sartans; therapeutic interventions
1. Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) induces delayed cerebral vasospasm (DCVS) [1],
cerebral inflammation [2,3], early brain injury [4], cortical spreading depression [5], delayed cerebral
ischemia (DCI) [6], and lack of cerebral autoregulation [7] contributing to poor functional patients’
outcome. DCVS remains a major cause of patient’s morbidity and mortality by inducing delayed
cerebral ischemia [8].
Multiple studies showed that endothelin-1 (ET-1), a most potent vasoconstrictor [9–11], plays a
key role in the development of DCVS [12–19]. Although endothelin-A-receptor (ETA-R) antagonists in
Brain Sci. 2020, 10, 153; doi:10.3390/brainsci10030153 www.mdpi.com/journal/brainsci57
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the treatment of DCVS in animal models are effective [10,20], clinical studies did not show beneficial
effects [21,22]. It has been reported that the polypeptide angiotensin-II acts through two specific
receptors, in essence the angiotensin-II-type-1- and angiotensin-II-type-2-receptor (AT2-1-R and
AT2-2-R). Important to note is that activation of the AT2-1-R results in vasoconstriction while binding
of angiotensin-II to the AT2-2-R causes vasorelaxation [23]. In line with this notion, preclinical as well
as clinical trials showed promising results of Sartans, which are AT2-1-R antagonists, in ischemic stroke.
Hence, Sartans may have a positive effect after aSAH by reducing DCVS due to crosstalk with the
endothelin system. Thus, we aimed to analyze the potential role of Sartans in the treatment of aSAH.
2. Materials and Methods
We conducted a systematic literature research of the MEDLINE PubMed database in accordance
with PRISMA guidelines on preclinical studies on the one and on clinical studies on the other hand
published between 1980 to 2019 reviewing: “Sartans and ischemic stroke” [24]. Only articles in English
were chosen for review. Search items with “Sartans” (n = 19,064) and “ischemic stroke” (n = 89,465)
were extracted. For “Sartans AND ischemic stroke”, 227 publications met the inclusion criteria by
excluding studies with commentary only, any duplicates, or results not commenting on cerebral
effects of Sartans.
Two hundred and twenty-seven studies were assessed for eligibility, 83 met inclusion criteria
for systematic review and qualitative analysis with 64 preclinical studies (Figure 1 demonstrates the
inclusion pathway for basic research studies selected via MEDLINE PubMed search) and 19 clinical
studies (Figure 2 shows the inclusion pathway for clinical research studies selected via MEDLINE
PubMed search).
Figure 1. Two hundred and twenty-seven articles (published 01-01-1980–01-07-2019) were detected for
preclinical and clinical research articles. After manual abstract screening for preclinical research articles
only, 79 articles remained for further analysis. Each of the 79 articles was explicitly screened for potential
drug applications after ischemic stroke. Finally, 64 articles were included for qualitative analysis.
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Figure 2. Two hundred and twenty-seven articles (published 01-01-1980–01-07-2019) were detected for
preclinical and clinical research articles. After manual abstract screening for clinical research articles
only, 46 articles remained for further analysis. Each of the 46 articles was explicitly screened for
potential drug applications after ischemic stroke. Finally, 19 articles were included for final analysis.
Of the articles included in the final analysis, a systematic review on the beneficial and non-beneficial
effect in the preclinical and clinical settings was performed. Summary measures are reported as
outcome measures (i.e., infarct size, neurocognition, inflammation).
3. Results
3.1. Preclinical Studies on Sartans in Animal Models of Ischemic Stroke
The search finally yielded 64 preclinical studies on “Sartans AND ischemic stroke”, eligible for
systematic review (Table 1).
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Telmisartan (TMS), a selective AT2-1-R antagonist, displayed the capacity to increase cerebral
blood flow (CBF) in global cerebral ischemia [25]. It ameliorated reduction of CBF in the penumbra
(0.3 mg/kg/day) without significant changes in blood pressure (BP) [28]. Following middle cerebral
artery occlusion (MCAO), TMS decreased ischemic infarct area, reduced superoxide production
and expression of inflammatory cytokines, infiltration of inflammatory cells, improved neurological
scores, and increased CBF [26,27]. Angiogenesis in ischemic areas after MCAO was enhanced by
TMS, as well as neuroregeneration by downregulating caspase activation [29]. A combination of
TMS with nimodipine (2.5–5 mg/kg) in a transient MCAO rat model revealed beneficial influences
affecting the attenuation of excitatory amino acids in different brain regions nine days after MCAO
with neurobehavioural outcomes normalized seven days after MCAO [31]. Low doses of TMS
(0.3–3 mg/kg/d) after MCAO in a model of stroke-resistant spontaneously hypertensive rats (SR-SHR)
reduced progressive decrease of N-acetylglucosamine oligomer and increase of MMP-9 positive
neurons without reducing BP [32]. Likewise combination therapies with ramipril (0.8 mg/kg per day
TMS + 0.1 mg/kg per day ramipril or 0.5 mg/kg per day TMS+ 0.25 mg/kg per day ramipril) normalized
BP as well as maintained cerebral blood flow autoregulation [33]. Deguchi et al. demonstrated that
TMS dose-dependently (0.3 mg/kg/day or 3 mg/kg/day) ameliorated metabolic syndrome related
changes in the post stroke brain of SR-SHR with direct neuroprotective effects [34]. Moreover, incidence
of stroke was reduced along with prolonged survival and improved neurological outcome following
TMS application (0.5 mg/kg once daily) [35]. Pretreatment of rats with TMS (1 mg/kg) seven days
before inducing cerebral ischemia also showed significant reduced infarct size and histopathologically
normal appearance of neurons in the periinfarct cortical regions [36].
Candesartan (CS), another AT2-1-R antagonist, reduced ischemic brain damage following MCAO
occlusion [39]. CS and curcumin together significantly restored superoxide dismutase activity and
blood flow compared with the untreated group [40]. Further, CS upregulated vascular endothelial
growth factor (VEGF) B after induction of focal cerebral ischemia using a MCAO model. In contrast
to saline-treatment after reperfusion, CS further improved neurobehavioral and motor functions
and decreased infarct size [41]. VEGF-B silencing was shown to diminish CS (1 mg/kg) protective
effects [42]. CS (0.3 mg/kg) was able to improve recovery from ischemic stroke in low doses by
maintaining blood pressure during reperfusion [43]. CS induced early protective effects with
improvement in motor function, upregulated brain-derived neutrotrophic factor (BDNF), and also
reduced endoplasmatic reticulum stress markers [44]. In a MCAO BDNF, knock-out model rats received
CS or saline at reperfusion for 14 days, revealing better functional outcomes, increased vascular density,
and synaptogenesis in the CS (1 mg/kg) group [45,46]. In addition, CS (0.16 μM) significantly increased
BDNF production [47]. Furthermore, CS (10 nM) improved cell function and viability of brain
capillary endothelial cells under oxygen glucose deprivation, providing protective blood–brain-barrier
(BBB) effects [48]. In other transient MCAO rat models, CS (0.1 mg/kg; 0.3 mg/kg; 1.5 or 10 mg/kg
per day; 0.1, 1 and 10 mg/kg; 0.1, 0.3 or 1 mg/kg; 0.1 mg/kg twice daily; 1 mg/kg; 0.3 or 3 mg/kg
per day; 0.5 mg/kg per day for 14 days; 0.1 or 0.3 mg/kg; 0.5 mg/kg per day for 3 to 14 days) showed
improved neurological function with significant reduction in BBB disruption, in cerebral ischemia,
and in edema [39,49–60]. In a bilateral common carotid artery occlusion (CCAO) model in rats,
pretreatment with CS (0.1 and 0.3 mg/kg) and atorvastatin significantly attenuated neurobehavioral
alterations, oxidative damage, and restored mitochondrial enzyme dysfunction compared to the control
group [61,62]. AT2-1-R administration prior to ET-1 induced MCAO provides neuroprotective effects,
with CS (0.2 mg/kg per day for seven days) pretreatment attenuating infarct size and neurological
deficits without altering systemic BP [63]. Pretreatment with CS for five days significantly decreased
mortality, neurological deficits, and infarct size [67]. A combined inhibition of AT2-1- (0.05 mg/kg per
day) and ETA-receptors decreased brain damage as well; additionally, an upregulation of AT2-1-R in
ischemic middle cerebral artery smooth muscle cells (SMCs) was found [68,69]. Also, early (3 h) and
delayed (24 h) effects of CS treatment (0.3 and 3 mg/kg) continued for seven days after onset of MCAO
with reperfusion in normotensive rats involved a reduction of the infarct volume by low doses of CS [70].
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CBF in CS (0.5 mg/kg) pretreated animals at 0.5 h after MCAO was significantly increased compared to
the control group [71]. Other groups additionally showed a four-week CS-pretreatment (0.3 mg/kg
per day) before MCAO clearly associated with complete reversal of a decreased lumen diameter and
increased media thickness as well as decreased endothelial nitric oxide synthase (eNOS) and increased
inducible nitric oxide synthase (iNOS) protein and mRNA in SR-SHR and in a normotensive control
group [72].
Olmesartan (OMS), an AT2-1-R antagonist, has been evaluated in a bilateral CCAO model in mice,
revealing improved cognitive outcome, neuroprotective effects, attenuation of oxidative hippocampal
stress, and suppression of BBB disruption compared to control groups [73]. A single carotid ligation
stroke model in gerbils showed that OMS (10 mg/kg per day started 36 h after stroke) was associated
with an increased survival [74]. Other studies demonstrated that OMS (10 mg/kg per day for 14 days
after infarct; 10 mg/kg per day for 7 days before and 14 days after infarct; 10 mg/kg per day for 7 days
before infarct) treatment in a rat MCAO model showed significantly better functional scores and
reduced infarct size and cell death [75]. OMS (0.01 or 0.1 μmol/kg per hour for seven days) reduced
brain angiotensin II, MMP-2 and MMP-9 upregulation following brain ischemia [77].
Valsartan (VS), a selective AT2-1-R antagonist, reduced ischemic brain area and improved the
neurological deficit after MCAO with restoration of cerebral blood flow [78]. VS significantly reduced
infarct volume and improved the neurological deficit scores. VS at nonhypotensive doses significantly
diminished ischemic area, neurological deficits, and reduction of cerebral blood flow as well as
superoxide production [27,78,80].
Irbesartan (IS), a selective AT2-1-R antagonist improved motor functions, reduced infarct size and
decreased the number of apoptotic cells particularly in the periinfarct area by attenuated invasion of
activated microglia likewise macrophages [82–84].
Losartan (LS), a clinical established selective AT2-1-R antagonist, did not increase mortality in
acute cerebral ischemia [85]. Also, LS (20 μmol/L) abolished ischemic exaggeration of cell injury [26,86].
Expression levels of pro-apoptotic genes were significant reduced by LS treatment [87]. Further LS
administration initiates cerebral angiogenic response with a significantly larger vessel surface area,
and administration before initiation of cerebral focal ischemia (50 mg/day for 2 weeks) markedly
reduces infarct size [88].
3.2. Clinical Studies on Sartans in Ischemic Stroke
The search yielded 19 clinical studies on “Sartans AND ischemic stroke”, eligible for systematic
review (Table 2). Beneficial aspects of using AT2-1-R antagonists before the onset of ischemic stroke
have already been elucidated in a retrospective analysis of 151 patients [89].
Table 2. Tabular listing of different clinical studies showing various effects of Sartan administration
(Abbreviations: Candesartan (CS); hours (h); losartan (LS); milligram (mg); minutes (min); μmol
(micromolar); modified ranking Scale (mRS); mol (molar); nmol (nanomolar); telmisartan (TMS);
valsartan (VS)).
Drug Outcome Beneficial Effect Special Remarks
CS [90]
Vascular event (vascular death,
nonfatal stroke or nonfatal myocardial
infarction) over 6 months and mRS
No overall effect on vascular events in
ischemic and/or hemorrhagic stroke,
adjusted odds ratio for vascular events of
patients treated within 6 h
reached significance
Administration at least within 30 h of
ischemic or hemorrhagic stroke. CS
treatment for 7 days, increasing from
4 mg on day 1 to 16 mg on day 3 to 7
CS [91] Barthel index and level of careassessed after 6 months
No significant effects on Barthel Index or
level of care at 6 months
Administration at least within 30 h of
ischemic or hemorrhagic stroke. CS
treatment for 7 days, increasing from
4 mg on day 1 to 16 mg on day 3 to 7
CS [92]
Vascular death, myocardial infarction,
stroke during first 6 months and
functional outcome at 6 months
Significant trend towards a better effect of
CS in patients with larger infarcts; no
differences in treatment effect for composite
vascular end point
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
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Table 2. Cont.
Drug Outcome Beneficial Effect Special Remarks
CS [93]
Vascular death, myocardial infarction,
stroke during first 6 months and
functional outcome at 6 months
After 6 months the risk of the composite
vascular endpoint did not differ between
treatment groups
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
CS [94]
Safety of modest blood pressure
reduction by CS cilexetil in the early
treatment of stroke
The cumulative 12 months mortality and
the number of vascular events differed
significantly in favor of the
CS cilexetil group
CS treatment with 4 mg on day 1;
dosage increased to 8 mg on day 2 or
16 mg if blood pressure exceeded
160 mmHg systolic or
100 mmHg diastolic
CS [95]
Short-term safety of blood pressure
reduction in hypertensive patients
with acute ischemic stroke
CS treatment safely reduces blood pressure
in hypertensive patients with acute
ischemic stroke
4 mg/day for 14 days
CS [96]
Adhesion of neutrophils to human
endothelial cells in acute
ischemic stroke
CS inhibited the adhesion of neutrophils to
vascular endothelium in ischemic stroke
patients (not in chronic stroke patients or
healthy volunteers)
Incubation with 10−9 mol for 30 min
CS [97]
Effect of blood pressure lowering in
patients with acute ischemic stroke
and carotid artery stenosis (Vascular
death, stroke, myocardial infarction,
and functional outcome at 6 months)
No evidence that CS effect is qualitatively
different in patients with carotid
artery stenosis
CS treatment for 7 days, increasing
from 4 mg on day 1 to 16 mg
on day 3 to 7
VS [98]
Safety of modest blood pressure
reduction within 48 h of acute
ischemic stroke
After 90 days the mRS as well the rate of
major vascular events differed not
significantly between both groups
80 mg/day (dose was modified in the
subsequent six-days of treatment if
the target systolic blood pressure was
not achieved)
VS [99] Effect of vs. on humanplatelet aggregation
VS exhibited significant inhibition of
human platelets and therefore might be
able to reduce vascular ischemic events
10 nmol to 100 μmol
TMS [100] Time to first recurrent stroke
Low glomerular filtration rate (<60
mL/min) is independently associated with a
higher risk of recurrent stroke, TMS not
able to mitigate this risk
TMS dosage not reported
TMS [101] Recurrent stroke of any type
Similar rates of recurrent strokes comparing
aspirin plus extended-release dipyridamole
with clopidogrel and TMS
80 mg/day
TMS [102] Prevention of cerebral whitematter lesions
TMS on top of existing antihypertensive
medication did not prevent the progression
of white matter lesions
80 mg/day. Analysis limited by the
relatively short follow-up
TMS [103]
Functional outcome at 30 days
(primary outcome), death, recurrence,
and hemodynamic measures up to
90 days (secondary outcomes)
TMS treatment appears to be safe with no
excess in adverse events and not associated
with a significant effect on functional
dependency, death, or stroke recurrence
80 mg/day
TMS [104] Recurrent stroke
TMS initiated soon after ischemic stroke
and continued for 2.5 years did not
significantly lower the rate of recurrent
stroke, major cardiovascular events, or
diabetes
80 mg/day
LS [105] Global change of cerebral blood flow LS treatment increases the global cerebralblood flow despite blood pressure lowering 50–100 mg/day for 4 weeks
LS [106]
Effect on stroke in patients with
isolated systolic hypertension and left
ventricular hypertrophy
Incidence of any stroke (40% risk
reduction), fatal stroke (70% risk reduction),
and atherothrombotic stroke (45% risk
reduction) was significantly lower in the
LS treated group compared to atenolol
treated patients
Mean LS dose of 79 mg
LS [107]
Effect on global and focal cerebral
blood flow in hypertensive patients
2–7 days after stroke
No neurological deterioration in the
LS group 25–50 mg/day
LS [108]
Spontaneous platelet aggregation and
P-selectin levels (in patients with
hypertension and chronic
ischemic stroke)
Spontaneous platelet aggregation was not,
P-selectin levels significantly reduced after
LS treatment. This suggests that standard
doses of LS display antiplatelet effect
50 mg/day
CS has been evaluated in the Scandinavian Candesartan Acute Stroke Trial (SCAST). Within 30 h of
ischemic or hemorrhagic stroke, 2029 patients either received CS- or placebo-treatment. The modified
ranking Scale (mRS) was used for outcome analysis. CS showed no overall effect on vascular events
in ischemic and/or hemorrhagic stroke, and the adjusted odds ratio for vascular events of patients
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treated within 6 h reached significance [90]. At six months, activities of daily living and level of care
were assessed. In more than 1800 patients, over 1500 suffered ischemic and almost 250 hemorrhagic
strokes. No statistically significant effects of CS on Barthel index or level of care could be identified [91].
Furthermore, the SCAST group evaluated whether the effect of CS treatment varies in subtypes of
over 1700 ischemic strokes. Concerning functional outcomes, a trend towards a beneficial effect
of CS was observed in patients with larger infarcts (total anterior circulation or partial anterior
circulation) than in patients with smaller lacunar infarcts [92]. Further on, over 2000 SCAST patients
were randomly allocated to placebo or CS treatment for seven days with increasing doses from 4 mg
(starting day 1) to 16 mg (from day 3 to 7). After six months’ follow-up, the risk of the composite
vascular endpoint did not differ between the placebo and CS treatment group [93]. Also, the Acute
Candesartan Cilexetil Therapy in Stroke Survivors study confirmed that administration of CS in the
acute phase of stroke in 339 patients confers long-term benefits in patients who sustained acute ischemic
stroke [94]. VS has been evaluated in a multicenter trial concerning efficacy and safety of modest
blood pressure reduction within 48 h in more than 370 patients with acute ischemic stroke, considering
the primary outcome death or dependency. The VS-treated group showed 46 of 187 patients with a
90-day mRS of 3–6, compared with 42 of 185 patients in the control group. The rate of major vascular
events did not differ significantly between both groups [98]. TMS has also been evaluated concerning
beneficial effects after stroke treatment. A multicenter trial, involving more than 18,500 patients
with ischemic stroke, had a follow-up of 2.5 years. The primary outcome parameter was time to
first recurrent stroke. Only short-term add-on TMS (80 mg/day) treatment did not mitigate this
risk [100,101]. Treatment with TMS (80 mg/day) did not prevent progression of white matter lesions
in patients with recent ischemic stroke [102]. Another study group enrolled 20,332 patients and
analyzed 1360 patients within 72 h of ischemic stroke onset (TMS vs. placebo) concerning functional
outcome after 30 days as primary outcome. Combined death or dependency did not differ between
the treatment groups, showing treatment with TMS (80 mg/day) in patients with acute mild ischemic
stroke and mildly elevated BP safe with no excess in adverse events [103]. Also, effects of TMS
(80 mg/day) initiation early after stroke have been analyzed. From 20,332 patients with recent ischemic
stroke, 10,146 patients were randomly assigned in the TMS group and 10,186 in the placebo group;
8.7% in the TMS group and 9.2% in the placebo group suffered from subsequent stroke, showing
no significant reduction of recurrent stroke after early initiation [104]. LS has also been analyzed in
recent clinical stroke trials. In a double-blinded multi-center trial, 196 hypertensive patients with
previous ischemic stroke were randomized to cilnidipine- or LS-treatment (50–100 mg per day for
four weeks) once daily for four weeks. Both treatments, however, increased global CBF despite BP
lowering [105]. Additionally, the effect of long-term therapy with LS regarding cognitive function
in 6206 essential hypertonic patients with additional cerebrovascular risk factors was investigated.
The LS-based antihypertensive treatment increased the proportion of patients with normal cognitive
function [109]. Also, the Losartan Intervention for Endpoint reduction in hypertension study group
reported cardioprotective effects of a LS-based antihypertensive regimen. The incidence of any
stroke, fatal stroke, and atherothrombotic stroke was significantly lower in LS-treated compared to
the atenolol-treated isolated systolic hypertensive patients [106]. Other groups assessed the effect
of LS treatment on mean arterial blood pressure, global, and focal CBF in 24 hypertensive patients
without occlusive carotid disease 2–7 days after ischemic stroke and/or transient ischemic attack.
LS (25–50 mg per day) was generally well tolerated and none of the patients suffered neurological
deterioration. No changes occurred in internal carotid artery flow or cortical as well as hemispheric
CBF [107].
3.3. Therapeutic Interventions After aSAH
Poor patients’ outcome after aSAH is owed a multifactorial process (early brain injury, DCVS,
DCI, cerebral inflammation, cortical spreading depression, loss of pressure dependent cerebral
autoregulation) [4,5,7,9,110–113]. DCVS is treated with moderate hypertensive, normovolemic,
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hemodilution, and in cases of therapy-refractory, DCVS with intra-arterial spasmolysis or balloon
dilatation [114,115]. Research to improve poor functional outcome in patients suffering from
aSAH and related DCVS is pivotal [1,5,21,116,117]. Multiple preclinical and clinical trials showed
the effect of ET-1 in mediating DCVS after aSAH. CONSCIOUS-1, a randomized, double-blind,
placebo-controlled study assessed the efficacy of intravenous clazosentan (ETA-R antagonist) in
preventing vasospasm following aSAH. It significantly decreased angiographic DCVS with a trend
for reduction in vasospasm-related morbidity/mortality [118]. CONSCIOUS-2 assigned patients
with aSAH and clip ligation to clazosentan- or placebo. Thereby, clazosentan showed no significant
difference in the mortality and vasospasm-related morbidity [119]. CONSCIOUS-3 assessed whether
clazosentan reduced DCVS-related morbidity and mortality after aSAH and endovascular coiling.
Pulmonary complications and anemia were more common in patients with clazosentan administration
than in the placebo group, and mortality rates after 12 weeks were the same, respectively [120].
The REVERSE-study, infusing clazosentan intravenously in patients developing moderate to severe
angiographic vasospasm after aSAH, showed a clear pharmacodynamic dilating effect on DCVS 24 h
in most patients suffering aSAH, being able to reverse established angiographic vasospasm [22].
Antihypertensive agents are usually discontinued to maintain a sufficient mean arterial cerebral
perfusion pressure considering the prolonged phase of DCVS between days 5 to 14 after the ictus [114].
In contrast, nimodipine, a calcium-channel antagonist, is administered for risk reduction of DCVS,
yet rather its neuroprotective effects have been discussed in its beneficial role in aSAH [8,121].
3.4. Effects of Losartan Following aSAH
LS, an already well-established antihypertensive drug in daily clinical practice and well examined
in preclinical and clinical settings of ischemic stroke, shows promising results by attenuating cerebral
inflammation and restoring cerebral autoregulation [64,105,122–125]. Facing preclinical aSAH research,
beneficial effects of Sartans have been shown. Under already physiological conditions, LS diminished
cerebral inflammation and associated DCVS [126] as well as ET-1 mediated vasoconstriction. Targeted
ETB1- and ETA-R-antagonism under LS administration revealed a direct modulatory ETB1-R dependent
effect via inducing upregulation of the NO-pathway with a significantly increased relaxation
accompanied with enhanced sensitivity of the ETB1-R [23]. After induction of aSAH, ET-1-induced
vasoconstriction was likewise decreased by LS preincubation, abolished after pretreatment with an
ETB1-R antagonist. In precontracted vessels with LS and ETA-R-antagonism, ET-1 induced a higher
vasorelaxation compared to the control group without, clearly demonstrating a modulatory and
functional restoring effect of LS on the normally after aSAH impaired ETB1-R function [127].
Beneficial effects of LS on ET-1- and PGF2α-mediated DCVS after aSAH in a rat model have been
reported, too [23,127]. An ET-1 mediated vasoconstriction was diminished, and ETB1-R mediated
vasorelaxation under selective ETA-R blockade was restored [126,127]. In addition, PGF2α-elicited
vasoconstriction of a basilar artery was markedly diminished [23,126,127]. Interestingly, several
work groups could also verify positive vasomodulating effects of LS on the cerebral vessel wall,
especially affecting SMCs [128,129]. Furthermore, aneurysm rupture was prevented in mice under
LS treatment [129]. As already mentioned, after aSAH, increased synthesis of ET-1 triggers enhanced
cerebral vasoconstriction; loss of the ETB1-R mediated vasorelaxation contributes to this effect, too [127].
Furthermore, upregulated AT2-1-R and PGF2α-synthesis contribute in enhancing and maintaining
cerebral vasocontraction [7,130–133]. LS showed promising aspects in preclinical aSAH studies and
therefore might have an effect in the treatment of patients with aSAH.
4. Discussions
This systematic review demonstrated Sartan administration after ischemic stroke clearly associated
with beneficial effects on preclinical models as well regarding clinical trials. Clear evidence of which
doses in preclinical and clinical settings for treatment of ischemic stroke with Sartans exactly might be
useful are heterogenous and therefore not consistent yet. In a preclinical setting, Sartans significantly
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reduced infarct volume and edema, augmented CBF, diminished superoxide production, inflammatory
processes, and disruption of the BBB. In clinical studies, clear trends towards a better functional outcome
and neurocognitive function after stroke with Sartan use have been reported. Thus, the question arises
whether Sartans might provide positive effects on DCVS or DCI after aSAH. In summary, LS provided
in a preclinical physiological and pathophysiological setup after aSAH beneficial aspects in reducing
ET-1- and PGF2α mediated cerebral vasoconstriction [126,130]. Vasoconstriction was notably reduced
and the vasorelaxant properties of the ETB1-R were restored. Furthermore, clear evidence exists,
that after aSAH, AT2-1-R are upregulated in experimental settings [132]. Here, an additive direct
antagonism on these receptors could reduce the sensitivity to an AT2-1-R-mediated vasocontraction to
angiotensin II, too [125,134]. LS possesses beneficial aspects on cerebral epileptogenicity, which could
be applied to the issue of reducing cortical spreading depression post aSAH [135–138]. Also, it is able
to restore post-ischemic cerebral autoregulation after hemorrhagic stroke [134].
Considering these neuroprotective effects of LS, the ethical question arises of whether the
philosophy of strictly discontinuing all antihypertensive agents after aSAH (except of new
administration of nimodipine), especially of LS, should stay state of the art. Next to beneficial
influences on DCVS after aSAH in rats as mentioned above, AT2-1-R antagonists clearly possess
beneficial effects after stroke regarding cerebral inflammation, the areal of infarction, cortical
spreading depression, cerebral microcirculation, and maintenance of pressure-dependent cerebral
vasoconstriction [23,64,71,105,127,134,139–141]. Appreciating these facts, a systemic LS administration
over and above the phase of DCVS, could be a promising approach in preventing these effects;
particularly because LS seems to not influence the global CBF in essential hypertonic patients, which
can be set equivalent to a needed-hypertonia after aSAH [142]. Here, LS could be an interesting
approach, because it increases global CBF despite lowering blood pressure [105], and is therefore
capable to reduce DCI [92]. Also, considering the positive vasomodulatory influences of LS, the question
arises whether after aSAH this medication should be established as secondary prophylaxis to avoid a
de-novo-aneurysm genesis, ergo, if aneurysms under LS are anyway arising [143].
4.1. Translational Aspects
Both abovementioned questions after aSAH are difficult to adapt to the affected patient group,
because common sense to date stays in discontinuing all antihypertensive agents after the initial
bleeding event. Also, it is vague to postulate that a LS effect persists after discharging this medication
on admission over the phase of DCVS for 14 days. Furthermore, the numbers of patients with LS
as standard antihypertonic medication receiving follow-up angiographys are too scarce to testify a
valid statement concerning case-control studies of aneurysm-growth/-development, as reviewed in
our own patient series in 2009–2015. Nevertheless, LS seems to be an underrated neuroprotective
drug, reducing cerebral inflammation and epileptogenicity, DCVS, and infarct size after ischemic
stroke. These results of preclinical ischemic stroke and aSAH research as well as clinical ischemic
stroke research could be applied in a prospective clinical setting of patients suffering aSAH. Also,
the question of a de-novo-aneurysm-genesis in further cranial control imaging could be addressed.
4.2. Synopsis and Forecast
LS, a selective AT2-1-R antagonist, was shown to directly antagonize and ameliorate the impaired
ETB1-R vasodilatory function. Given that in most clinical centers, antihypertensive agents are
discontinued during the period of DCVS, LS, although an antihypertensive drug, may have a role in
preventing delayed DCVS after aneurysm rupture given the effects shown in ischemia. Following
aSAH, immediate therapy with LS might antagonize the vasoconstrictive AT2-1-R without affecting the
dilatory AT2-2-R effect [132,144–151]. Furthermore, AT2 interestingly increases endothelin production
in non-cerebral vessels (an increased ET-1 concentration in rat aortas could be inhibited through LS
administration [140]) and thus indirectly enhances ET-1-mediated DCVS [123,152–156]. All these
aspects might suggest a crosstalk between both peptidergic systems extra- and intracranially [71,157].
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5. Conclusions
There is a promising effect on LS in the treatment of ischemic stroke both in preclinical and
clinical studies as well as in preclinical studies on aSAH. LS has shown to reduce ET-1-mediated
vasocontraction, cerebral inflammation, and restores vasodilatory function of the ETB1-R [26–28]. Thus,
LS may decrease the incidence of symptomatic vasospasm and improve functional outcome in aSAH
patients. Large, randomized, double-blinded clinical trials are necessary to determine its benefit
in aSAH.
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Abstract: Intracranial aneurysms (IA) are characterized by weakened cerebral vessel walls that
may lead to rupture and subarachnoid hemorrhage. The mechanisms behind their formation and
progression are yet unclear and warrant preclinical studies. This systematic review aims to provide a
comprehensive, systematic overview of available animal models for the study of IA pathobiology.
We conducted a systematic literature search using the PubMed database to identify preclinical
studies employing IA animal models. Suitable articles were selected based on predefined eligibility
criteria following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. Included studies were reviewed and categorized according to the experimental animal
and aneurysm model. Of 4266 returned results, 3930 articles were excluded based on the title
and/or abstract and further articles after screening the full text, leaving 123 studies for detailed
analysis. A total of 20 different models were found in rats (nine), mice (five), rabbits (four), and dogs
(two). Rat models constituted the most frequently employed intracranial experimental aneurysm
model (79 studies), followed by mice (31 studies), rabbits (12 studies), and two studies in dogs.
The most common techniques to induce cerebral aneurysms were surgical ligation of the common
carotid artery with subsequent induction of hypertension by ligation of the renal arteries, followed
by elastase-induced creation of IAs in combination with corticosterone- or angiotensin-induced
hypertension. This review provides a comprehensive summary of the multitude of available IA
models to study various aspects of aneurysm formation, growth, and rupture. It will serve as a useful
reference for researchers by facilitating the selection of the most appropriate model and technique to
answer their scientific question.
Keywords: animal model; aneurysm; cerebral aneurysm; intracranial aneurysm
1. Introduction
Intracranial aneurysm (IA) refers to an outward bulging of the arterial wall and is a serious
cerebrovascular disease with a high morbidity and mortality [1]. It is characterized by a chronic
inflammation and weakening of the arterial walls [2]. The prognosis of IA is poor, due to a rupture of the
lesions and the ensuing subarachnoid hemorrhage that is responsible for the high number of IA-induced
fatalities. Even though the prevalence of IA is high (2–8% [3]), there is currently no proven therapy that
achieves stabilization and prevention of rupture. Most IA patients are treated conservatively, and only
those with a presumably high risk of IA rupture (depending on the IA size, smoking status and
location [4]) undergo occlusion [5]. The successful development and implementation of therapeutic
strategies to avoid IA formation, and particularly subarachnoid hemorrhage, is hence of clinical
importance. A prerequisite for any effective therapy is a better understanding of IA pathobiology.
Moreover, both the efficacy and potential side effects of a novel drug need to be carefully assessed before
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it may be administered to IA patients, requiring a thorough preclinical investigation that precedes the
translation in the clinical practice. Since the natural formation of IA is rare in animals, techniques to
artificially induce IA in experimental animals have been developed. Researchers interested in the study
of IA pathobiology are now facing a broad variety of animal models to choose from [6]. These involve
models in different species and numerous variations of the originally developed methods, which differ
in their comparability to human IAs, the complexity of the methodology, and the questions that can be
answered. Furthermore, the technique to induce hypertension constitutes a common variation of the
initial, well-established models. The large volume of available models may complicate the selection of
the appropriate model for the respective research question. We therefore set out to compile systematic
literature review on available IA animal models as a comprehensive reference for researchers planning
to employ such a model in their investigations. We discuss advantages and disadvantages of each
model and address considerations regarding the species and method of choice.
2. Materials and Methods
A systematic literature search in the Medline/PubMed database was conducted to identify
preclinical studies using IA animal models. The search was performed on November 31, 2017 with
the keywords “mice”, “rat”, “rabbit”, “dog”, and “swine” in combination with “aneurysm” using the
Boolean operator [AND]. Studies on primates were excluded due to their limited ethical justifiability.
The search was restricted to “animals”. Two investigators (SM and FS) independently screened
titles and abstracts and selected suitable studies based on predefined eligibility criteria following the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [7]. The final articles
to be included were selected based on the full text of eligible studies. Discrepancies in the study
selection were discussed with all authors and a consensus was reached. Included studies were reviewed
and categorized according to the experimental animal used and the aneurysm model employed.
The eligibility criteria were as follows: (1) in vivo IA model in the experimental species rat, mouse,
rabbit, dog, and swine; (2) English language; (3) original research article (reviews, letters, and editorials
were excluded).
The following data were extracted from eligible full text articles: (1) authors and year of publication;
(2) study question and main conclusion; (3) animal species; (4) method to create IA; (5) IA location;
and (6) time until sacrifice/study duration.
The same method to generate IA in different species was considered a separate model.
Modifications of an existing model such as extension of the technique itself or of significant accessory
techniques (e.g., induction of hypertension by renal artery (RA) ligation) were also categorized as
individual models.
3. Results
The literature searches initially returned 4264 articles, of which 3930 were excluded after title
and/or abstract screening because they did not meet the eligibility criteria. A further 211 articles were
excluded after screening the full text due to one or more of the following reasons: duplicate article,
article was withdrawn, the type of article differed from an original research study such as a review,
letter or comment, or the article was written in a language other than English. This strategy left
123 studies for a detailed analysis (Figure 1).
A total of 20 different models were identified based on the technique to create IA (common
carotid artery (CCA) ligation (unilateral or bilateral), (renal artery [RA] ligation [unilateral or bilateral],
elastase injection [with or without CCA ligation] and experimental species [rat, mouse, rabbit, dog]))
(Table 1). Only those modifications that affected the ligation surgery (i.e., RA ligation or not) were
considered as separate models. Smaller variations to the induction of hypertension (i.e., different
NaCl concentrations, β-aminopropionitrile monofumarate (BAPN) or estrogen depletion) were not
considered as novel models. Of the identified distinct models, 9 different models were used in rats, 5 in
mice, 4 in rabbits, and 2 in dogs (see Table 1 for detailed listing of studies according to the IA model).
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The identified IA animal models were assigned to one of the following main categories: (1) CCA
ligation with concomitant RA ligation, (2) CCA ligation only, (3) elastase injection, (4) elastase injection
and CCA ligation, or (5) another model.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart
for study selection.
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The most common technique to induce cerebral aneurysms was surgical ligation of the CCA
and/or the RA with concomitant induction of hypertension (64 studies), followed by CCA ligation
without RA manipulation (24 studies) and elastase-induced creation of IAs in combination with
corticosterone- or angiotensin II-induced hypertension (24 studies, see Table 2 for an overview of IA
model by experimental animal). Thirteen studies employed alternative methods to create IA. Of the
models using CCA ligation, unilateral ligation of the left CCA was performed in most models, but
ligation of the right CCA or bilateral ligation was also common. CCA ligation was most common in rats
and rabbits, whereas the elastase method was used in most mouse models. The category “other models”
included IA creation by deoxycorticosterone administration [121], eplerenone administration [122],
induction of copper deficiency [123], CaCl2 treatment [124], coating of the internal carotid artery [125],
with one study for each of these models.
Table 2. Number of aneurysm type per species in the included studies. The vast majority (76%) of
studies in rats used a combined CCA ligation and RA ligation model, whereas most mouse studies













Mice 31 4 1 21 4 -
Rats 79 60 13 1 - 5
Rabbits 21 - 10 1 1 -
Dogs 2 - - - - 2
Overall 133 64 24 22 5 6
Most of the assessed studies used rats for their animal model (79 studies), followed by mice
(31 studies), and rabbits (12 studies). Only two studies were performed in dogs. Almost half of the mouse
models were employed in transgenic animals [22,41,43,53,92,95,96,99,102,105,106,109,112,114,127].
The most frequent variation of the original models was modification of the technique to induce
hypertension rather than of the IA creation technique itself. Hypertension was typically achieved
by using one or a combination of RA ligation, high salt diet, or deoxycorticosterone administration
(Table 3). A further variation of the original CCA model was omission of BAPN administration to
inhibit cross-linking of collagen and elastin, which was contraindicated depending on certain research
questions [56].










Mice (31) 3,4 (0,5–5) 13 (0) 0,53 (0,17–1) 0,43 (0,1–0,75) -
Rats (79) 2,28 (0,17–12) 2,49 (0,25–12) 1,25 (0) - 1,83 (1–2,5)
Rabbits (12) 3,0 2,59 (0,17–6) 1,5 (1–2) -
Dogs (2) - - - - 0,68 (0,35–1)
Overall 2,38 (0,17–12) 2,53 (0,17–13) 0,65 (0,17–2) 0,43 (0,1–0,75) 1,37 (0,35–2,5)
The study duration before sacrifice and assessment of the animal varied between a few
weeks [38,105] and a year [16,71], but typically lasted 1 to 3 months.
4. Discussion
By conducting a comprehensive systematic review of the literature, we achieved categorization of
the IA animal models available to date and developed an overview that should facilitate the choice of
the experimental animal and most appropriate technique for researchers interested in IA pathobiology.
Surgical ligation of the CCA and elastase-induced weakening of the arterial vessel wall was identified as
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the predominant techniques to create IA in experimental animals. A brief discussion of the advantages
and disadvantages of each of these categories follows.
General Considerations
Ethics: Animal ethics regulations have become increasingly strict in recent years in terms of the
species of animal and required numbers to be used in experimental studies. Studies on animals that
raise particular ethical concerns, such as those conducted in dogs, primates and swine, are likely to
face more obstacles throughout the animal ethics approval process, which may delay the conduction of
the study or entirely prevent its completion. Small animals that are more commonly used in research
such as rats and mice appear often more feasible than those in large animals, yet the study needs
to be carefully designed to ensure statistically feasible justification of the required animal numbers,
particularly in cases where it is unknown if and for how long the animals will survive the experiment,
as is the case for all intracranial animal models.
Costs: Similar to the ethical concerns, the maintenance and housing of large animals can infer
tremendous costs on the researcher. In addition, the potential costs need to consider the duration of
the experiments, as some of the aneurysm models last for more than three months, during which time
the animals need to be housed and likely monitored daily, which results in additional costs for animal
care personnel and veterinarians.
Reliability: Most intracranial aneurysm models are conducted in rats by unilateral CCA ligation
and concomitant RA ligation (Table 2). This can be attributed to the reliability of such a model in
producing aneurysms in the majority of experimental animals in a comparatively very short period
of time of less than three months (Table 3). These models are so reliable because they are based on
a long history of refinement and modifications, Table S1 tweaking the technique to a point where
aneurysm development is guaranteed. An even faster generation of aneurysms is observed in the
elastase model in mice, yet it appears that this model does not work well in rats, therefore one needs
to balance the time of formation with the most suitable species for the experiment. The best model
clearly depends on the research question to be answered. If aneurysm growth is the main factor to
be investigated, surgical ligation models are to be favored over others, as the procedure allows for
variation in the size of the aneurysm and may generate very large aneurysms in the animals. In turn,
if aneurysm rupture is the center of the investigation, the surgical model needs to be combined with a
treatment to induce hypertension such as administering NaCl in the drinking water or implanting a
salt pellet with dosed release. Alternatively, the elastase model is frequently used in mechanistic and
pharmacological aneurysm rupture studies as it generates ruptures through subarachnoid hemorrhages
within a relatively short period of time (one month).
Ligation of the CCA, with or without concomitant RA ligation: This original model first described
in the 1970s by Hashimoto et al. [11] and Nagata et al. [78] involves unilateral ligation of the CCA, for
which most frequently the left CCA is manipulated. The ligation is accompanied by additional induction
of hypertension using either ligation of one or both RAs, feeding of a high salt diet, administration of
deoxycorticosterone, or a combination of these parameters (Table 4). In order to increase the animal’s
susceptibility to IA formation and shortening of the IA induction time, CCA ligation may be combined
with administration of β-aminopropionitrile, a lathyrogen that inhibits the cross-linking of collagen
and elastin, or with estrogen depletion achieved by oophorectomy to compromise endothelial cell
function and NO (nitrogen oxide) release. Most rat models employ unilateral CCA ligation combined
with bilateral RA ligation and a high salt diet, while in rabbits, both CCAs are often ligated without
any further means of inducing hypertension. In mice, unilateral CCA ligation was complemented by
contralateral ligation of one RA.
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Table 4. Variations to established IA models pertaining to the technique to induce hypertension and
weaken vessel walls.
Technique Purpose Number of Studies Number of Species
RA ligation, unilateral Hypertension 12 3
RA ligation, bilateral Hypertension 52 2
High NaCl diet (1% or 8%) Hypertension 68 3
Deoxycorticosterone administration Hypertension 15 3
Angiotensin II Hypertension 13 1
β-aminopropionitrile administration (0.12%) Weakening of vessel walls 36 2
Estrogen depletion/oophorectomy Weakening of vessel walls 12 3
Note: several methods may have been used concomitantly in the same animal or study. High NaCl diet followed by
bilateral RA ligation were the most commonly used techniques. RA = renal artery; NaCl = sodium chloride.
The major advantage of this model is that is has been well established and refined for decades
and has been shown to reliably induce IA in rats, mice and rabbits. It has been employed to answer
a broad variety of research questions, ranging from the contribution of isolated factors to aneurysm
formation to the success of therapeutic agents in the prevention and treatment of IAs.
Elastase treatment: As an alternative to the classical vessel ligation model, several more recent
studies employ the injection of elastase into the cerebrospinal fluid or a common artery to disrupt the
elastic lamina and thereby weaken the vessel walls. Concomitant induction of hypertension is achieved
by continuous administration of angiotensin II with the aid of an implanted osmotic mini-pump, or by
a combined administration of a high salt diet and deoxycorticosterone. This model is employed in
mice and rabbits but rarely in rats. It accomplishes creation of large aneurysms within a relatively
short study period. In a few models, both the injection of elastase and artery ligation were performed.
Elastase treatment and ligation of the CCA: IA generation by elastase injection may be supported
by concomitant ligation of the CCA. We identified only four studies that employed this model, and mice
were the only experimental animal used. Hence, this model has apparently not been tested in other
experimental animals. Of note, this model involved the shortest study period, with IA creation
achieved several days following the induction and a mean generation time of less than half a month









CCA ligation CCA and RA
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Study duration for aneurysm creation
Figure 2. Meta-analysis of all intracranial aneurysm models to determine the shortest required
study period for intracranial aneurysm (IA) generation. Common carotid artery (CA) ligation alone
or in combination with renal artery (RA) ligation typically involved a period of several months,
while intracranial aneurysms could be created by elastase injection with or without common carotid
artery ligation in one month or less. Bars indicate mean + SD.
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Once the type of IA model has been identified, the choice of experimental animal species must
be considered, considering that the situation in the animal should be comparable to human IA
pathophysiology. Most IA models are performed in small animals such as rats and mice. A limitation
of all models is that IA do not easily develop spontaneously in animals and hence always constitute an
artificially induced entity.
Certain models apparently work better in one species than the other [25]. The total study duration
needs to be estimated; e.g., how long does it take to induce an aneurysm in an animal, and is this
duration feasible for the study setting? We performed a meta-analysis of all selected studies with
regards to the time it took to develop IAs following the induction (Figure 2, Table 3). Elastase injection
alone (0.65 ± 0.43 months), or in combination with CCA ligation (0.43 ± 0.38 months), required a
shorter time for IA generation than CCA alone (2.53 ± 3.33 months) or in combination with RA ligation
(2.38 ± 2.48 months; Figure 2). The shortest study period was observed in a mouse model with elastase
injection (0.1 month), while a model with CCA ligation in mice (13 months) took the longest (Table 3).
In addition, the number of animals that can be used is determined by the breeding time, housing
space and animal care cost, and is to be carefully considered to obtain an animal number that can
reach statistical significance (Collaborative Approach to Meta-Analysis and Review of Animal Data
from Experimental Studies/CAMARADES [128]). Furthermore, different strains of the same species
may differ in their susceptibility to IA formation [36]. Practical aspects also play a role in the species
choice, such as the space that is required for the surgery (e.g., can it be done in a designated laboratory
space or is an operating theater required) and the level of difficulty of the surgery itself (e.g., is an
anesthesiologist required, how technically challenging is the surgery). The estimation of whether the
respective research question can be appropriately answered with the experimental animal species is of
utmost importance. For example, if the contribution of an isolated factor is to be investigated, a strain
with a genetic knockdown of the gene of choice may be useful, which then renders a genetic mouse
model the most suitable choice. Animal ethics need to be considered as well, as canine studies are
not only expensive but also ethically challenging. Concerns over the ethical treatment of animals led
to the development of the “3R principle” that aims to replace, reduce, or refine experiments using
experimental animals; owing to this principle, primates are rarely used these days as research models.
For this reason, we did not extend the scope of the present review to this species as they are only
employed in exceptional cases. Advantages and disadvantages of each model are discussed as follows.
Rats: The major advantage of using rats as an experimental model is the availability of a
well-established model that works well and has been described in detail with slight variations for
decades. CCA ligation in combination with RA ligation appears to be the gold standard for IA creation,
and the investigator can make a well informed choice of the experimental specifications due to the
plethora of available literature. Furthermore, rats are commonly used experimental animals, are easily
available, instill only moderate costs for housing and feed, and breed fast, making it possible to conduct
studies with many animals to reach statistical significance. Moreover, anesthetic techniques are well
established in this species and can be easily maintained in a typical research laboratory without the
need for a designated operating theater or a veterinary anesthesiologist. The surgery is manageable
(not as small as in the mouse but still comparable to humans) and may be relatively easily learned by a
new scientist entering the field. The disadvantage of using rats is that the elastase model apparently
does not work as well in rats as in mice, and neither does bilateral CCA ligation should it be required.
In addition, although genetic knockout models in rats are available, they generate considerably higher
costs compared to such models in mice.
Mice: Mice share the same practical advantages as rats, in that their housing and feed is
comparatively cheap, they breed fast, and are well maintained during surgery on basic anesthetic
techniques. The major advantage of using mice as an experimental model is the possibility to investigate
an isolated factor that may contribute to IA formation or protect from it in transgenic animals, be it
knockout mouse models or animals overexpressing certain genes. Particularly, the elastase model is
well established in mice, and the CCA ligation model has also been successfully employed in this
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species. A disadvantage of using mice may be the somewhat delicate surgery on very small vessels,
which could require some practice to achieve an optimum outcome.
Rabbits: Bilateral CCA ligation is particularly well established in rabbits and appears to work
better in this species than in rats. None of the studies included in this review employed RA ligation in
rabbits, and only one study described the elastase model. In terms of practicability, rabbits incur a
somewhat larger cost for housing than rats and mice as they require more space. It may also not be
possible to conduct surgery on these animals in any regular laboratory space, but rather an operating
theater might be required.
Dogs: We identified only two studies using distinct IA models in dogs as experimental animals,
both of which were dated (1977 and 1984). It has to be noted that angiography is an investigative
technique available for dogs that does not require sacrifice of the animal. Nevertheless, it appears
that both the much more extensive cost in combination with ethical considerations does not render
this species a model that can be routinely employed. The same holds true for swine and primates
as experimental animals to create IAs. Few studies exist that use large species to produce IAs.
The few published studies are considered historical series rather than models that are still in use today.
Considering ethical concerns, it is unlikely that these species/models will gain importance in the future.
5. Conclusions
We provide a categorization of available IA animal models and thereby present a tool to guide
researchers entering the field of aneurysm pathobiology. The best choice of a specific IA model strongly
depends on the individual research question and numerous other factors such as the primary endpoint,
available resources (e.g., expenses for animal housing and breeding, space for surgical procedures,
need for veterinary anesthesiologist), and time frame for IA initiation, growth, and rupture (weeks
to months).
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3425/10/3/134/s1,
Table S1: Incidence of Aneurysm development.
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Abstract: Background. Most available large animal extracranial aneurysm models feature healthy
non-degenerated aneurysm pouches with stable long-term follow-ups and extensive healing reactions
after endovascular treatment. This review focuses on a small subgroup of extracranial aneurysm
models that demonstrated growth and potential rupture during follow-up. Methods. The literature
was searched in Medline/Pubmed to identify extracranial in vivo saccular aneurysm models featuring
growth and rupture, using a predefined search strategy in accordance with the PRISMA guidelines.
From eligible studies we extracted the following details: technique and location of aneurysm creation,
aneurysm pouch characteristics, time for model creation, growth and rupture rate, time course, patency
rate, histological findings, and associated morbidity and mortality. Results. A total of 20 articles were
found to describe growth and/or rupture of an experimentally created extracranial saccular aneurysm
during follow-up. Most frequent growth was reported in rats (n = 6), followed by rabbits (n = 4),
dogs (n = 4), swine (n = 5), and sheep (n = 1). Except for two studies reporting growth and rupture
within the abdominal cavity (abdominal aortic artery; n = 2) all other aneurysms were located at the
neck of the animal. The largest growth rate, with an up to 10-fold size increase, was found in a rat
abdominal aortic sidewall aneurysm model. Conclusions. Extracranial saccular aneurysm models
with growth and rupture are rare. Degradation of the created aneurysmal outpouch seems to be a
prerequisite to allow growth, which may ultimately lead to rupture. Since it has been shown that the
aneurysm wall is important for healing after endovascular therapy, it is likely that models featuring
growth and rupture will gain in interest for preclinical testing of novel endovascular therapies.
Keywords: animal model; growth; aneurysm rupture; saccular; intracranial aneurysm
1. Introduction
Increased understanding of the complex pathobiology of intracranial aneurysm (IA) growth,
rupture, and the effects of endovascular therapy depends on epidemiological data analysis, clinical
findings, histopathology of IA samples obtained during surgery, and gene linkage analysis [1–5]
Experimental work using animal models of IA are needed to delineate the biological mechanisms of
IA formation and growth, and to establish new medical and endovascular therapies and materials
to prevent IA rupture. Cerebral aneurysm models can be divided into two large groups: Intra- and
extracranial models [6].
There is a growing body of evidence that the aneurysm wall condition influences the healing
response and long-term durability after endovascular therapy [7–10]. Most available extracranial
aneurysm models feature healthy non-degenerated aneurysm pouches with stable long-term follow-ups
and extensive healing reactions after endovascular treatment [11]. This review focuses on a small
Brain Sci. 2020, 10, 101; doi:10.3390/brainsci10020101 www.mdpi.com/journal/brainsci99
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subgroup of extracranial saccular aneurysm models that demonstrate growth and potential rupture
during follow-up. It is likely that this subgroup of models will become more important for challenging
the testing of devices prior to their clinical application [6,7,12]. This systematic review provides
a comprehensive overview of available techniques and associated characteristics of extracranial
aneurysm models featuring growth and rupture. Furthermore, this summary serves as reference for
the development of novel models and supports researchers in the planning and execution of their
future experiments.
2. Materials and Methods
2.1. Literature Search
The literature was searched in Medline/Pubmed on November 31, 2017 to identify extracranial
in vivo saccular aneurysm models featuring growth and rupture using a predefined search strategy.
Briefly, we used the following key words: “murine”, “rat”, “rabbit”, “canine”, “primate”, “cat”, “pig”,
”sheep”, and “goat” in combination with “intracranial aneurysm” using the Boolean operator [AND].
The search was restricted to animals and two investigators (SM and FS) independently screened titles
and abstracts for eligible studies and removed duplicates. Full text analysis of the remaining articles
determined their final eligibility. Uncertainties by the two investigators were discussed with a third
examiner (BG). Cross-references were searched until no further studies were identified. The search
algorithm was in accordance with the PRISMA guidelines.
2.2. Eligibility Criteria and Analyzed Features
We considered all preclinical extracranial saccular aneurysm models with documented growth
and/or rupture. We excluded in vitro experiments, studies on intracranial vessels, studies published in
a language other than English, articles designed for the study of thoracic or abdominal aortic aneurysms,
and review articles. From each study included in the final analysis we recorded the following: authors,
year of publication, aneurysm model category (sidewall, terminal, stump, bifurcation, and complex),
species, detailed technique of aneurysm creation, aneurysm pouch characteristics (vital or modified,
arterial or venous), initial size and location of the aneurysms, time for model creation, growth rate
and time course of growth, size of increase (as percentage of baseline), rupture rate and time course,
patency rate, mortality and morbidity rate, and histological findings.
3. Results
A total of 20 articles were found that described growth and/or rupture of an experimentally
created extracranial saccular aneurysm. The initial electronic search yielded 4264 potential studies.
Of these, 3788 articles were excluded after title and abstract screening and 4 articles were excluded
after identification of duplicates. The remaining 472 articles underwent full text analysis. Of those, 405
studies were excluded according to the predefined eligibility criteria. Another 48 studies describing
various saccular aneurysm models were excluded because none of the reported techniques resulted in
growth or rupture of the created aneurysms. One study was added by cross-referencing (Figure 1).
Growth and/or rupture of experimental aneurysms were found in three types of models: sidewall
(n = 12) [3,8,13–22], bifurcation stump (n = 6) [14,23–27], and terminal (n = 3) [28–30]. Most frequent
growth was reported in rats (n = 6) [8,14,16,23–25], followed by rabbits (n = 4) [13,21,26,29], dogs
(n = 4) [19,27,28,30], swine (n = 5) [3,17,18,20,22], and sheep (n = 1) [15]. Except for two studies
reporting growth and rupture within the abdominal cavity (abdominal aortic artery; n = 2) [8,16] all
other aneurysms were located at the neck of the animal (common carotid artery; n = 18). The identified
20 models used in n = 14 venous pouches (in n = 2 of them inverted venous pouches [3,30]), in n = 3
modified arterial pouches (n = 2 porcine elastase [26,29] and n = 1 sodium dodecyl sulfate [8]), and
in n = 3 direct mechanical arterial wall weakening [13,23,24] to create growing and rupture-prone
100
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aneurysms. Time for aneurysm creation was reported in only two studies (180 minutes each for a
terminal model in dogs [28] and rabbits [29]).
Figure 1. PRISMA flow chart for study selection.
Almost half (n = 9 out of 20) of the models demonstrated growth only without associated rupture
during follow-up. The volume increase varied greatly between the models used and ranged between
tiny blebs [23] and a 10-fold increase [8] in initial size. Most models (n = 17 out of 20) reported only
modest increase, with stabilization at further follow-up. The largest increase in aneurysm volume was
found in rat sidewall aneurysm models created in the abdominal cavity. Growth rate and time course
of growth ranged from 23% to 100% and from weeks to months, respectively.
More than half (n = 11 out of 20) of all identified models reported rupture during follow-up.
In three out of these eleven models the aneurysm wall was modified at the time of creation [8,26,29].
Intraluminal aneurysm thrombosis was present in 9 out of 11 models featuring rupture. Rupture
occurred within a few days and up to months after aneurysm creation. Except for a single case of
rupture within one day all other ruptures occurred later than day 3 after creation, irrespective of the
model applied. The rate of rupture ranged from 7% to 100% depending on the model used. Associated
morbidity and mortality ranged from 0% to 50%. Three studies did not report associated morbidity
and mortality rate.
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The predominant histological findings in growing and ruptured aneurysms are: unorganized
intraluminal thrombus, incomplete neointima formation with partial aneurysm recurrence, marked
inflammatory cells within unorganized thrombus and aneurysm wall, hemorrhagic transformation of
the aneurysm wall with intramural loss of endothelial cells, smooth muscle cells, and degradation
of extracellular matrix components. All details of each model and associated characteristics are
summarized in Table 1.
4. Discussion
Most extracranial aneurysm models differ from human saccular aneurysms not only in their
histology, but their reluctance towards growth and rupture. In consequence, aneurysm growth and/or
rupture during follow-up are rare events. This review demonstrates that the following characteristics
seem to be associated with growth and rupture of extracranial saccular aneurysms, regardless of the
species or model used: intraluminal aneurysm thrombosis, intraluminal and intramural inflammation,
endothelial and mural cell loss, and hemorrhagic transformation of the aneurysm wall. Most of the
identified 20 extracranial saccular aneurysm models were of sidewall type and featured only short-term
aneurysm maturation rather than true aneurysm growth during follow-up.
After pioneering work on aneurysm creation by direct vessel manipulation on extra- and
intracranial arteries by McCune et al. [31] and White et al. [32] it was Troupp and Rinne [13] who
demonstrated the growth of sidewall carotid aneurysms in rabbits created by an arteriotomy glued with
methl-2-cyanoacrylate. They found significant increase in size in 30% of aneurysms over a time of 1 to
5 months. Many models demonstrate maturation by means of aneurysm enlargement in the first weeks
after creation but remaining stable thereafter [24–26,28,30]. Nishikawa et al. [14] and Gao et al. [24]
demonstrated growth by means of maturation in rat venous pouch sidewall and bifurcation aneurysms.
Fujiwara et al. [26] found a similar increase in size within the first four weeks with a further stable
course of up to 4 months in an elastase arterial bifurcation stump model in rabbits. Naggara et al. [30]
also found a maturation/growth within the first month and then stable course up to 10 months after
creation of venous pouch terminal aneurysms in dogs. This may be explained by the absence of true
perivascular inflammation and normal cellularity of the aneurysm walls. This healthy venous vascular
tissue that the aneurysms were made of may have been able to organize to allow cell migration, and to
synthesize a new extracellular matrix, eventually resulting in aneurysm healing. In contrast, the largest
increase in size and true growth (ten-fold increase in size compared to baseline) was found in a rat
abdominal aortic arterial pouch sidewall aneurysm model [8]. This remarkable growth was probably
only possible due to aneurysm wall decellularization and the fact that the abdominal cavity is less
restrictive than the subcutaneous soft tissue of the neck region.
More than half (55%) of the identified models demonstrated rupture of the experimental aneurysm
during follow-up. In almost half of the reported models that demonstrate rupture, the aneurysm wall
had been modified at the time of creation (Table 1). However, in all these models that featured rupture,
the aneurysm wall was either weakened during creation (chemically or mechanically) or demonstrated
marked wall degeneration (inflammation and intraluminal thrombosis) at autopsy. Stehbens [15]
reported in 1979 that 30% (8/27) of venous sidewall aneurysms created at the common carotid artery in
sheep ruptured within three weeks after creation. All these ruptured aneurysms contained macroscopic
thrombus. Raymond et al. [3] demonstrated that 100% (7/7) of giant and 50% (2/4) of small-neck swine
common carotid artery sidewall venous pouch aneurysms ruptured within 1–2 weeks after creation.
They found that many areas of the aneurysm wall showed a lack of smooth muscle cells and elastic
fibres but had inflammatory cells infiltrating the wall, along with hemorrhagic transformation of the
media, adventitia, and perianeurysmal tissue. Yang et al. [29] presented a terminal rabbit aneurysm
model with an arterial pouch modified with both elastase and collagenase. In this model, aneurysms
grew within the first 1–2 weeks in 100% of cases (10/10) and 33% (3/9) of them ruptured within 4 weeks
after creation. Histopathology revealed that the aneurysm wall was composed only of a thin layer
of acellular fibrous tissue. Decellularization of the aneurysm wall in a sidewall rat aneurysm model
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resulted in aneurysm growth in 33% (4/12) and rupture in 25% (3/12) [8]. Decellularized aneurysms in
this model demonstrated inflammation and damage to the aneurysm wall and marked neutrophil
accumulation in the luminal thrombus.
In summary, loss of mural cells and chronic aneurysm wall inflammation is a crucial factor for
both saccular aneurysm growth and rupture. It has been demonstrated that aneurysms that lost mural
cells also lost their ability to organize luminal thrombus and to form a neointima [8,33]. Instead,
ongoing inflammation results in destructive wall remodeling, further mural cell loss and thinning
of the vascular wall which in turn favors further aneurysm growth and rupture. Thus, in order to
establish a model which can reflect true aneurysm growth and rupture instead of just a short-term
maturation, artificial rarefication of mural cells is necessary.
In addition to intracranial animal models for the study of aneurysm formation and rupture, it will
be essential to further develop larger extracranial animal models that will allow to study embolization
devices and healing processes in growing and rupture-prone aneurysms. Although most valuable,
aneurysm models featuring growth and rupture are ethically questionable due to potential sudden
death. Close monitoring (e.g., ultrasound imaging) to regularly check for the hemodynamic situation
is recommended in all experimental aneurysm models featuring growth and rupture [3,8,34].
5. Conclusions
Extracranial saccular aneurysm models with growth and rupture are rare. Most of these models
presented the increases in aneurysm size by means of maturation rather than ongoing degradation of
the aneurysm wall and true growth that ultimately results in aneurysm rupture. Histological findings
suggest that degradation of the wall (either by direct manipulation at the time of creation or indirect
weakening mediated through intraluminal thrombosis and inflammation) is essential for rupture of
an artificially created saccular aneurysm model. Since it has been shown that the aneurysm wall is
important for healing after endovascular therapy, it is likely that models featuring growth and rupture
will gain interest in the preclinical testing of novel endovascular therapies.
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Abstract: We report diffusion tensor tractography (DTT) of the corticospinal tract (CST) in a patient
with paresis of all four limbs following subarachnoid hemorrhage (SAH) with intraventricular
hemorrhage (IVH) after the rupture of an anterior communicating artery (ACoA) aneurysm rupture.
The 73-year-old female was admitted to our emergency room in a semi-comatose mental state. After
coil embolization—an acute SAH treatment—she was transferred to our rehabilitation department
with motor weakness development, two weeks after SAH. Upon admission, she was alert but she
complained of motor weakness (upper limbs: MRC 3/5, and lower limbs: MRC 1/5). Four weeks
after onset, DTT showed that the bilateral CSTs failed to reach the cerebral cortex. The left CST
demonstrated a wide spread of fibers within the corona radiata as well as significantly lower tract
volume (TV) and higher fractional anisotropy (FA) as well as mean diffusivity (MD) compared to the
controls. On the other hand, the right CST shifted to the posterior region at the corona radiata, and
MD values of the right CST were significantly higher when compared to the controls. Changes in
both CSTs were attributed to vasogenic edema and compression caused by untreated hydrocephalus.
We demonstrate in this case, two different pathophysiological entitles, contributing to this patient’s
motor weakness after SAH.
Keywords: subarachnoid hemorrhage; ventriculomegaly; diffusion tensor imaging; corticospinal tract
1. Introduction
Anterior communicating artery (ACoA) aneurysms are the most common intracranial aneurysms
and account for approximately 30% to 37% of subarachnoid hemorrhage (SAH) [1]. After aneurysm
rupture, the resulting subarachnoid hemorrhage can result in complications such as cognition
impairment [2]. However, motor weakness is also one of the neurological complications of SAH [3].
Many studies have used diffusion tensor tractography (DTT) to visualize neural tracts in the
human brain, and as a result, DTT provides a useful means of evaluating neural tract injuries in human
brain [4–6]. However, no DTT study has been performed examining the mechanisms responsible for
motor weakness in the limbs of patients during the subacute phase following SAH with intraventricular
hemorrhage (IVH). We hypothesize that, based on our DTT finding, that the injury of the corticospinal
tract (CST) is due to SAH with intraventricular hemorrhage (IVH).
2. Case Presentation
A 73-year old female patient without a relevant prior medical history was admitted to our
emergency room in a semi-comatose mental status (Glasgow Coma Scale: 3). Computed tomography
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(CT) revealed a modified Fisher grade 4 SAH due to the rupture of a ACoA aneurysm, with consecutive
hydrocephalus due to IVH (Figure 1A) [7]. After coil embolization, the patient was neurosurgically
treated by hematoma evacuation and placement of an external ventricular drainage (EVD) (Figure 1B).
Nimodipine was administered according to standing guidelines [8]. Two weeks after the initial ictus
and upon improvement of her mental status, the patient was later transferred to our rehabilitation
department. Upon admission, her mental status was altered, however, with reduced motor function of
the upper and lower extremities (medical research council (MRC) grading of 3 in upper extremities and
1 in lower extremities). Bladder and bowel functions were preserved. We performed brain magnetic
resonance imaging (MRI) at approximately week 4 after onset because of recovery of the CST within
two weeks due to the resolution of peri-lesional edema or inflammation after stroke [9]. The result
showed bilateral ventriculomegaly (Evan’s index: 0.35) with ventricular capping, encephalomalacia in
both frontal lobes, but no demarcated cerebral infarctions (Figure 2A).
Figure 1. (A) Initial computed tomography (CT) images showing subarachnoid hemorrhage (SAH) with
intraventricular hemorrhage (IVH) and consecutive ventriculomegaly, resulting from a ruptured anterior
communicating artery aneurysm (ACoA). (B) CT image after coil embolization and external ventricular
drainage (EVD) placement. Coil embolization (yellow arrow), EVD (white arrow), craniotomy site at
the right frontal lobe (red arrow), and ACoA (white dashed circle). Note: EVD; external ventricular
drainage, R, right; L, left; A, anterior; P, posterior.
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Figure 2. (A) Brain magnetic resonance images obtained at week 4 after onset showing clearance
of subarachnoid blood with persisting bilateral ventriculomegaly (Evan’s index: 0.35) with
interstitial edema and encephalomalacia in both frontal lobes (severe enlargement of the left
ventricle). (B) (a) Changes in both CSTs were observed around both lateral ventricles due to bilateral
ventriculomegaly versus the control subjects (70 years old female, white arrow) and a discontinuity of
both tracts to the bilateral cortex was apparent (white dash circle) (b) control. (C) (a) The right CST
did not extend to the right cortex (yellow arrow) and (b) the left CST spread out (green dash arrow).
(D) CSTs of a control subject. (E) (a) The right CST (red) was posteriorly shifted at the corona radiata
(orange arrow) and the left CST (yellow) was spread out compared with control subjects (white dashed
circle). (b) Left and right CSTs of a control subject. Note: R, right; L, left; A, anterior; P, posterior.
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3. Diffusion Tensor Imaging
DTT images were obtained using a 3.0 T GE Signa Architect MRI System (General
Electric, Milwaukee, WI, USA). The MRI preset conditions were as follows: field of view =
240 × 240 mm, acquisition matrix of 128 × 128, b = 1000 mm2·s−1, TR (repetition time) = 15,000 ms,
TE (echo time) = 80.4 ms, slice thickness = 2 mm, 30 directions, and 72 contiguous slices. DTT images
were analyzed using DTI studio software (www.mristudio.org, Johns Hopkins Medical Institute,
Baltimore, USA). The CST was reconstructed using two regions of interest (ROIs). The seed ROIs were
placed on the lower anterior pons and the target ROI was placed on the corona radiata. Termination
criteria for fiber tracking were a fractional anisotropy (FA) of <0.2 and a turning angle of >60◦. Mean
diffusivities (MDs), tract volumes (TVs), and FAs of the CST tracks were measured. Results were
compared with seven age-matched healthy control subjects (two males with a mean age of 70.14 years,
age range 67–78 years) in this study. In prior analysis, we defined pathological changes as a deviation
from reference values with at least two standard deviations [10]. At four weeks after onset, DTT
revealed curved changes of both CSTs around both lateral ventricles due to bilateral ventriculomegaly
compared with control subjects (Figure 2B). Furthermore, the right CST was shifted to the posterior
region at the corona radiata without reaching the cerebral cortex, which was called the discontinuation
(Figure 2B,C). The left CST appeared more spread out compared to the controls when looking at
subcortical white matter and showed only a few fibers reaching the cerebral cortex (Figure 2B,C,E). FA
and TV values of the left CST and MD values of both CSTs exhibited differences of two (SD) compared
to our reference values (Table 1).
Table 1. Diffusion tensor tractography (DTT) parameter values of the corticospinal tracts of the patient
and control subjects.
FA TV MD (×10−3 mm2/s)
Patient Right 0.632 3106.000 0.879 **
Left 0.666 ** 2148.000 ** 0.763 **
Controls (n = 7) Subject 1 (F/78) 0.617 3211.500 0.714
Subject 2 (F/70) 0.598 2703.500 0.712
Subject 3 (M/67) 0.623 2704.500 0.691
Subject 4 (F/68) 0.612 2998.500 0.717
Subject 5 (M/70) 0.633 3150.000 0.694
Subject 6 (F/68) 0.624 3203.500 0.724
Subject 7 (F/70) 0.607 3047.000 0.715
Mean (SD) 0.616 (0.017) 3002.643 (218.341) 0.709 (0.012)
SD, standard deviation; F, female; M, male; CST, corticospinal tract; FA, fractional anisotropy; TV, tract volume; MD,
mean diffusivity. ** Parameters were two SDs above or below mean normal control subject values.
4. Discussion
The corticospinal tract (CST) constitutes the main white matter motor pathway [11]. In this patient
with generalized motor weakness after SAH, the CST was investigated using DTT MRI imaging.
Bilateral CST reconstruction using DTT revealed side-dependent differences between our subject in
comparison to a matched cohort of control patients. More specifically, changes in CST structures were
observed around the corona radiata and lateral ventricle; the right CST had moved posteriorly and the
left CST was spread out at the level of the corona radiata, compared to the healthy controls. Apart
from displacement, the CSTs revealed signs of discontinuation at the cerebral cortex. Furthermore,
in the left CST, the FA and MD values were elevated and TV values reduced, and in the right CST, the
MD values were alerted due to a greater or lower difference than two standard deviations compared
with the control subjects.
FA values represent degrees of directionality at a microscopic level [10,12,13], and thus provide a
means of assessing microstructural integrity of axons, myelin, and microtubules [4,14]. On the other
hand, MD values provide quantitative measures of water diffusion, and are indicative of pathological
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changes taking place in white matter [15]. Increases in the values of MD represent vasogenic edema or
axonal damage whereas a decrease in MD values indicates neural injury [16]. TV values represent
numbers of voxels within neural tracts [16]. Therefore, FA and TV reductions in combination with MD
increases indicate the presence of neural injury [6,16].
In a previous study, it was reported that patients with normal pressure hydrocephalus (NPH)
had initial high FA values, explained by mechanical compression and decreased FA and increased
MD values as a result of secondary degenerative changes [3,17,18]. In this case, our patient exhibited
bilateral displacement and discontinuation of CSTs before reaching the cerebral cortex. In addition,
our MR imaging revealed high FA and MD values in combination with low TV value in the left CST.
However, the FA value of the right CST was not increased significantly. Based on these findings,
we hypothesized that the mechanism of motor weakness in our case was different between sides. At
week 4 after onset, posterior displacement of the right CST, as the result of hydrocephalus caused
ventriculomegaly, resulted in a discontinuation of the tract to the cerebral cortex. Significantly high MD
values were found with the number of voxels contained within neural tracts and FA values remaining
unchanged. We believed that the changes to the right CST are mainly caused by vasogenic edema
without neural injury, leading to the discontinuation of the tract resulting loss of left motor function. In
contrast to our results during the subacute phage, a previous study reported the formation of vasogenic
edema following SAH in the acute phase [19]. Further MRI assessment of the timely development of
vasogenic edema after SAH is necessary. However, in the left CST, spreading within the corona radiata
was observed due to ventriculomegaly caused mechanical compression. This, based on the observed
increased FA values, decreased TV, and increased MD indicative of degenerative change or neural
tract injury. These observations led to the paralysis of right limbs. However, we were able to exclude
age-associated microstructural changes because while age-associated microstructural changes using
DTT showed increased FA and MD values, our patient reveal no reduced FA value [20]. Additionally,
as a previous study, the analysis of CST for upper and lower limbs using DTT is difficult due to the
discontinuation of CSTs at the cerebral cortex [21]. However, we believe that a few fibers to the cerebral
cortex could play a role in upper motor function and tracts associated with lower motor function were
injured due to a compression of lateral ventricle and their discontinuation. However, the defined
causes of mechanical compression on the left side there and vasogenic edema in the right side were not
defined as effects at four weeks after SAH, so further study is required.
Therefore, at four weeks after onset (subacute phase), injury of the left tracts resulted from
degenerative change of the tracts (increased MD value and decreased TV value) and mechanical
compression (increased FA value). Damage to the right CST caused vasogenic edema by
ventriculomegaly. We believe that because of the larger left ventricle, mechanical compression
had greater influence on the left CST in terms of increasing FA. In other words, we indicate that
mechanical compression and degenerative changes by ventriculomegaly can coexist and induce tract
injury. In addition, we believe that the right CST injury resulted from vasogenic edema based on
differences in morphology of the tract caused by the difference in ventricle size.
The most feared complication following SAH is delayed cerebral ischemia. To prevent delayed
cerebral ischemia, our patient administrated aspirin and cilostazol [8]. Another complication is
hydrocephalus [7]. The patient received an EVD during the acute phase and was constantly being
monitored for persisting hydrocephalus. Previous studies have also presented mechanisms of motor
weakness after SAH or NPH [3,17]. It has been suggested that one of the mechanisms of paraplegia or
paraparesis after SAH is hydrocephalus [3]. However, to the best of our knowledge, this case report
is the first to observe a side-dependent different mechanism resulting in motor weakness as a result
of asymmetrical hydrocephalic ventriculomegaly (mechanical compression at the left hemisphere
and vasogenic edema at the right hemisphere). However, this study has some limitations, as follows:
(1) The external validity of these observations remains limited because they are based on a single
case, larger scale long-term studies are necessary to confirm our hypothesis; (2) As our study was in
the subacute phase, long-term follow up is necessary; (3) DTT interpretation is operator-dependent,
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leading to potential performance bias [11]; and (4) Finally, further clarification via electrophysiological
examination of long fiber tracts would have been helpful, but was hindered due to the existing
craniotomy defect [22].
5. Conclusions
Although DTT is subjected to operator-dependency [11], we can conclude a coexistence of
side-dependent compressive and degenerative damage to the CST caused by either ventriculomegaly
or direct compression, leading to bilateral motor weakness. Here, DTT was proven to be a useful tool
in assessing the mechanism behind post-SAH persisting motor weakness.
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Abstract: Intracranial hemorrhage (ICH) is a catastrophic complication in patients with acute
myeloid leukemia (AML). AML cells, especially in the acute promyelocytic leukemia subtype,
may release microparticles (MPs), tissue factor (TF), and cancer procoagulant (CP) to promote
coagulopathy. Hyperfibrinolysis is also triggered via release of annexin II, t-PA, u-PA, and u-PAR.
Various inflammatory cytokines from cancer cells, such as IL-1β and TNF-α, activate endothelial cells
and promote leukostasis. This condition may increase the ICH risk and lead to poor clinical outcomes.
Here, we present a case under a unique situation with acute ICH detected prior to the diagnosis of
AML. The patient initially presented with two episodes of syncope. Rapidly progressive ICH was
noted in follow-up computed tomography (CT) scans. Therefore, we highlight that AML should be
among the differential diagnoses of the etiologies of ICH. Early diagnosis and timely intervention are
very important for AML patients.
Keywords: syncope; acute myeloid leukemia; intracranial hemorrhage; hyperleukocytosis; blast crisis
1. Introduction
Intracranial hemorrhage (ICH) is an uncommon complication in patients with acute myeloid
leukemia (AML), and coincides with poor clinical outcome. The mortality rate of AML patients
developing acute ICH is high and death can occur within days if not diagnosed and treated
appropriately. In a study by Owattanapanich et al. [1], 4.29% (38/685 patients) AML patients
presented with ICH and acute promyelocytic leukemia had a higher risk of ICH with odds ratio of
6.15, compared to other types in the AML subgroup analysis [1]. Few patients with acute myeloid
leukemia in undifferentiated type presented syncope and ICH as an initial presentation. AML with
undifferentiated type (AML-M1) patients were presented with ICH accounting for only 15.79%
(6/38 patients). In addition, only 10% of patients present hyperleukocytosis, which are at higher risk of
tumor lysis syndrome and leukostasis [2]. Several risk factors were investigated, including hypertension,
vasculopathy, thrombocytopenia, lower coagulation factors, disseminated intravascular coagulation
(DIC), and hyperleukocytosis. Hyperleukocytosis and DIC were two major factors associated with
ICH. The incidence of hyperleukocytosis in acute AML patients was 5–20% and this condition
may be significantly associated with DIC, leukostasis, and tumor lysis syndrome, promoting ICH
events. However, clinical experiences concerning ICH in AML are limited in the literature. Therefore,
early diagnosis and timely intervention are crucial for AML patients. Here, we describe a rare case of
syncope at initial presentation in an AML-M0 patient with acute intracranial hemorrhage.
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2. Case Presentation
This case report was approved by the Institutional Review Board of Taipei Tzu Chi Hospital,
Buddhist Tzu Chi Medical Foundation (IRB number: 08-CR-060).
A 31-year-old male presented with a productive cough and rhinorrhea for 4 days. He had no past
medical history or medicine history. The symptoms were associated with intermittent high fever up
to 39–40 ◦C and myalgia. He took symptomatic treatment but in vain. The patient went to a local
medical doctor for treatment. While waiting outside the consulting room, syncope occurred twice and
he contused the frontal area. There was no tonic or clonic seizure. Other symptoms, including skin
rash, arthritis, or tendency for abnormal bleeding, were not found. Pneumonia-induced sepsis was
suspected, and he was transferred to our emergency department. Upon admission, his temperature
was 38.4 ◦C, blood pressure was 110/62 mmHg, heart rate was 129 beats/min, body weight was 90.6 kg,
and height was 173 cm. Upon physical examination, his Glasgow Coma Score (GCS) score was E4V5M6
and bilateral pupil size was 2 mm with light reflex. There was no horizontal or vertical nystagmus.
The neck was supple with no limited range of motion. The bilateral breath sound was clear without
wheezing or crackle, and tachycardia was noted. There was no Babinski sign, decreased muscle
power, or unsteady gait. The chest X-ray revealed no significant pulmonary nodules or pneumonia
patch. An influenza A + B rapid screening test was performed, which showed negative results.
A brain CT revealed a 13 mm lesion with hyperdensity in the left temporal region, with suspected
intracerebral hemorrhage (Figure 1). Laboratory evaluation of the patient revealed severe leukocytosis
with blastemia (Table 1).
Figure 1. On the day 1 brain computed tomography (CT), a 13 mm lesion with hyperdensity was
found in the left temporal region, with suspected intracerebral hemorrhage. On the day 2 brain CT,
multifocal intracranial hemorrhages in bilateral cerebral hemispheres were noted, the largest being
a 30 mm lesion in the left thalamus. The midline structures were shifted to the right side. Extensive
swelling was present in the cerebellum and brain stem.
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Table 1. The laboratory evaluation in this patient.
Variables Normal Range
Patient Data
Day 1 Day 2 Day 3 Day 4
White cell count 3.5–11 × 109/L 56.1 54.6 51.3 59.0
Band form neutrophils 0–3% 0.0% 0.0% 0.0% 0.0%
Segment form neutrophils 45–70% 0.0% 0.0% 0.0% 0.0%
Lymphocytes 25–40% 16.0% 7.0% 4.0% 6.0%
Eosinophils 1–3% 0.0% 0.0% 0.0% 0.0%
Monocytes 2–8% 6.0% 0.0% 0.0% 0.0%
Basophils 0–1% 0.0% 0.0% 0.0% 0.0%
Myelocytes 0.0% 0.0% 1.0% 0.0% 1.0%
Nucleated red blood cells 0.0% 0.0% 0.0% 0.0% 3.0%
Blast 0.0% 84.0% 92.0% 96.0% 93.0%
Hemoglobin 7.45–9.93 mmoL/L 5.40 4.65 4.47 5.28
Platelet counts 150–400 × 109/L 64 54 146 130
Blood urine nitrogen 2.5–6.4 mmoL/L 7.5 7.9 7.1 —-
Creatinine 0.04–0.09 mmoL/L 0.168 0.1591 0.1591 —-
Sodium 136–145 mmoL/L 138 144 157 147
Potassium 3.5–5.1 mmoL/L 2.8 2.2 4.1 2.7
Glucose 3.9–5.6 mmoL/L 6.3 —- —- —-
Alanine aminotransferase 0.27–1.05 μkat/L 0.50 —- 0.55 —-
High-sensitive Troponin I 0–19 ng/L 82.1 —- —- —-
C-Reactive Protein <31.4 nmoL/L 810.5 —- —- —-
Prothrombin time 8.0–12.0 s 12.7 12.1 12.7 —-
Partial thromboplastin time 23.9–35.5 s 26.8 26.5 25.0 —-
FDP-Ddimer 0–500 μg/L 708.18 552.51 —- —-
Results from the bone marrow biopsy report showed 90% cellularity. Blasts accounted for
more than 90% of all nucleated cells. Hypercellular and monotonous bone marrow was noted with
undifferentiated myeloblasts with prominent, convoluted nuclei, and agranular cytoplasm. There were
significantly decreased erythroid and megakaryocyte lineages. The immunohistochemical profile
was as follows: CD34(+), CD117(+), MPO(+), CD33(+), CD68(–), hemoglobin A(–), Factor VIII(–),
CD19(–), CD3(–), TdT(–), and PAX5(–). The peroxidase and alpha naphthyl acetate esterase (ANAE)
test was positive and chloroacetate esterase (CAE) test was negative. Acute myeloid leukemia was
diagnosed. Broad-spectrum antibiotic and adequate hydration were administered. An antineoplastic
agent, hydroxyurea (15 mg/kg/day), and emergency leukocytapheresis were used to control disease
progression. Unfortunately, the patient became drowsy with asymmetric pupil size and no light
reflex. The follow-up brain CT showed multifocal intracranial hemorrhage in the bilateral cerebral
hemispheres with midline shift involving the brain stem (Figure 1). Progressive hypotension was
noted even using a vasopressor agent. Finally, the patient expired due to uncontrolled hemodynamic
shock on the fourth day.
3. Discussion
In the AML population, intracranial-hemorrhage-induced syncope at initial presentation is
an uncommon but fatal condition. The study by Balmages et al. [3] showed a similar AML case
with hyperleukocytosis (WBC count of 51.7 × 109/L) was reported. In those populations, there was a
significantly higher risk of death from rapidly developed fatal ICH. In the study by Chen et al. [4], a total
of 841 AML patients were enrolled, and 6% (51/841 patients) were diagnosed with ICH. The location of
ICH was common at supratentorium (44/51 cases), followed by basal ganglion (9/51 cases), cerebellum
(5/51 cases), and brainstem (4/51 cases). The analysis of clinical outcome revealed that 67% of patients
(34 patients) died of ICH within 30 days of diagnosis. Severe DIC and leukostasis are two main causes
leading to ICH. In the untreated AML population, 5–20% of patients may present with hyperleukocytosis,
defined by white blood cell counts > 100,000/mL [5,6]. The hyperleukocytosis may result from a rapid
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blast proliferation and hematopoietic cell adhesion dysfunction [7]. Hyperleukocytosis may induce
DIC, tumor lysis syndrome, and leukostasis. The brain and lungs are the common organs involved,
and are associated with a high mortality rate. Severe hyperleukocytosis may induce mechanical
obstruction of small vessels, causing malperfusion, endothelial damage, subsequent hemorrhage,
and cell death [8]. The mechanical obstruction may be induced by myeloblasts via release of various
inflammatory cytokines and factors, such as IL-1β and TNF-α, to promote endothelial cell activation [9].
The activated endothelial cells increase the expression of adhesion receptors, such as intracellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Figure 2). However,
cytokine-driven endothelial cell activation, which is induced by AML, may lead to a loss of vascular
integrity and impaired endothelial antithrombotic function [10,11]. The endothelial damage can then
lead to impaired myeloblast migration and subsequent hemorrhage.
 
Figure 2. In an APL model, the acute myeloid leukemia (AML) cell produces microparticles (MPs),
tissue factor (TF), and cancer procoagulant (CP), which act on the coagulation cascade to promote
coagulopathy. The release of annexin II, t-PA, u-PA, and u-PAR from AML cells converts plasminogen
into plasmin, causing hyperfibrinolysis. Various inflammatory cytokines from cancer cells, such as
IL-1β and TNF-α, also activate endothelial cells and promote leukostasis.
In the study by Dixit et al. [12], DIC was found in 16.6% of AML patients (4/24 patients; M2: 1 case,
M3: 2 cases, M5: 1 case). Acute promyelocytic leukemia is a subtype of AML, characterized by fatal
bleeding events, and has also been well investigated [13]. Coagulopathy may be induced by AML
cells via high expression of tissue factor, activating the coagulation cascade. In an APL model, the
cells expressed high levels of three main procoagulants, including microparticles (MPs), tissue factor
(TF), and cancer procoagulant (CP) [14]. TF is a cell surface receptor that catalyzes the conversion
of factor X into factor Xa through factor VIIa. CP is a cysteine protease procoagulant involving the
coagulation cascade by activating factor X to promote thrombin [15]. MPs decrease coagulation time in
AML and promote coagulopathy via increased thrombin generation [16]. High levels of annexin II,
t-PA, u-PA, and u-PAR were also found to activate plasminogen into plasmin in AML cells, which
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induced hyperfibrinolysis [17,18]. In addition, endothelial cells may be destroyed via release of various
inflammatory cytokines, such as IL-1β and TNF-α, to promote DIC (Figure 2) [19].
Leukapheresis in AML patients with hyperleukocytosis rapidly removes excessive leukocytes by
mechanical separation to control complications. One round of leukapheresis could reduce the WBC
count by about 10–70% [20]. The efficacy of leukapheresis has been reported in previous clinical trials,
but there are some trials that disagree. After leukapheresis, AML cells may rapidly mobilize from
the bone marrow to peripheral blood. In addition, the benefit of leukapheresis was not significant in
clinical trials and the long-term outcome was not changed. However, leukapheresis may be beneficial
for preventing leukostasis and reducing the risk of ICH. A study by Novotny et al. [21] included 95
hyperleukocytic leukemia patients and evaluated the effectiveness of therapy using the four-stage
clinical grading scale. The results showed that the AML M1/M2 population with hyperleukocytosis
(p = 0.011), lower hemoglobin (p = 0.004), and blast crisis (p = 0.004) presented with highly probable
leukostasis with a high score. A subgroup was given early leukapheresis treatment which showed
a benefit (based on a grading score) in preventing leukostasis-related early death. In our case,
hyperleukocytosis with thrombocytopenia and blast crisis was noted. Leukapheresis was performed
but the treatment was not very effective. Persistent leukostasis and DIC promoted the progression of
ICH with multiple focal hemorrhages in day 2 CT scans.
4. Conclusions
In this article, we present the rare and unusual case of a patient with AML-induced ICH initially
presenting with syncope. In the AML population, DIC and leukostasis play a critical role in ICH.
This detailed pathophysiology may improve physicians’ development of therapeutic strategies for
AML-induced ICH. Here, we highlight the clinical features and etiologies of AML-induced ICH.
Early diagnosis and timely leukapheresis may prevent fatal progressive complications.
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